3/31/20213/31/202110-Q10-QfalsefalseMarch 31, 2021March 31, 202100017556720000030554December 31December 3120212021Q1Q1Large Accelerated FilerNon-Accelerated FilerFalseFalseFalseFalseFalseTrue0.010.010.011,666,667,0001,666,667,0001,666,667,000738,321,000743,458,000748,369,0003,8743,8573,4060.130.13833854000000410000005002.3011712012012010210210223,00023,0001,6731,67370070023,00023,00023,0000.300.300.301,800,000,0001,800,000,0001,800,000,000200200200———23,000,00023,000,00023,000,0001,673,0001,673,0001,673,000120120120———23,000,00023,000,00023,000,000700,000700,000700,0001021021023,8743,8573,4061.1251.1250.8750.8751.629200017556722021-01-012021-03-310001755672dd:EIDMember2021-01-012021-03-310001755672us-gaap:CommonStockMember2021-01-012021-03-310001755672dd:EIDMemberdd:A3.50SeriesPreferredStockMember2021-01-012021-03-310001755672dd:EIDMemberdd:A4.50SeriesPreferredStockMember2021-01-012021-03-31xbrli:shares00017556722021-04-30iso4217:USDxbrli:shares0001755672dd:EIDMember2021-04-30iso4217:USD00017556722020-01-012020-03-310001755672us-gaap:PensionPlansDefinedBenefitMember2021-01-012021-03-310001755672us-gaap:PensionPlansDefinedBenefitMember2020-01-012020-03-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-01-012021-03-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-01-012020-03-3100017556722021-03-3100017556722020-12-3100017556722020-03-310001755672dd:TotalcompanyMember2021-01-012021-03-310001755672dd:TotalcompanyMember2020-01-012020-03-3100017556722019-12-310001755672us-gaap:CommonStockMember2019-12-310001755672us-gaap:AdditionalPaidInCapitalMember2019-12-310001755672us-gaap:RetainedEarningsMember2019-12-310001755672us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001755672us-gaap:NoncontrollingInterestMember2019-12-310001755672us-gaap:RetainedEarningsMember2020-01-012020-03-310001755672us-gaap:NoncontrollingInterestMember2020-01-012020-03-310001755672us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310001755672us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-310001755672us-gaap:CommonStockMember2020-03-310001755672us-gaap:AdditionalPaidInCapitalMember2020-03-310001755672us-gaap:RetainedEarningsMember2020-03-310001755672us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-310001755672us-gaap:NoncontrollingInterestMember2020-03-310001755672us-gaap:CommonStockMember2020-12-310001755672us-gaap:AdditionalPaidInCapitalMember2020-12-310001755672us-gaap:RetainedEarningsMember2020-12-310001755672us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001755672us-gaap:NoncontrollingInterestMember2020-12-310001755672us-gaap:RetainedEarningsMember2021-01-012021-03-310001755672us-gaap:NoncontrollingInterestMember2021-01-012021-03-310001755672us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001755672us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001755672us-gaap:CommonStockMember2021-03-310001755672us-gaap:AdditionalPaidInCapitalMember2021-03-310001755672us-gaap:RetainedEarningsMember2021-03-310001755672us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001755672us-gaap:NoncontrollingInterestMember2021-03-310001755672dd:InternalReorganizationMember2020-01-012020-03-31xbrli:pure0001755672dd:AccountsandNotesReceivableMemberdd:DuPontdeNemoursMember2021-03-310001755672dd:DuPontdeNemoursMemberus-gaap:OtherAssetsMember2021-03-310001755672dd:DuPontdeNemoursMemberus-gaap:OtherNoncurrentLiabilitiesMember2021-03-310001755672dd:AccruedandOtherCurrentLiabilitiesMemberdd:DowMember2021-03-310001755672dd:DowMemberus-gaap:OtherNoncurrentLiabilitiesMember2021-03-310001755672dd:AccountsandNotesReceivableMemberdd:PerformanceChemicalsMember2021-03-310001755672us-gaap:OtherAssetsMemberdd:PerformanceChemicalsMember2021-03-310001755672dd:AccruedandOtherCurrentLiabilitiesMemberdd:PerformanceChemicalsMember2021-03-310001755672us-gaap:OtherNoncurrentLiabilitiesMemberdd:PerformanceChemicalsMember2021-03-310001755672dd:PerformanceChemicalsMember2021-01-012021-03-310001755672srt:MinimumMember2021-03-310001755672srt:MaximumMember2021-03-310001755672dd:AccruedandOtherCurrentLiabilitiesMember2021-03-310001755672dd:AccruedandOtherCurrentLiabilitiesMember2020-12-310001755672dd:AccruedandOtherCurrentLiabilitiesMember2020-03-310001755672us-gaap:OtherNoncurrentLiabilitiesMember2021-03-310001755672us-gaap:OtherNoncurrentLiabilitiesMember2020-12-310001755672us-gaap:OtherNoncurrentLiabilitiesMember2020-03-310001755672dd:MajorProductLineMember2021-01-012021-03-310001755672dd:CornMemberdd:SeedMember2021-01-012021-03-310001755672dd:CornMemberdd:SeedMember2020-01-012020-03-310001755672dd:SoybeanMemberdd:SeedMember2021-01-012021-03-310001755672dd:SoybeanMemberdd:SeedMember2020-01-012020-03-310001755672dd:OtheroilseedsMemberdd:SeedMember2021-01-012021-03-310001755672dd:OtheroilseedsMemberdd:SeedMember2020-01-012020-03-310001755672dd:SeedMemberdd:OtherMember2021-01-012021-03-310001755672dd:SeedMemberdd:OtherMember2020-01-012020-03-310001755672dd:SeedMember2021-01-012021-03-310001755672dd:SeedMember2020-01-012020-03-310001755672dd:CropProtectionMemberdd:HerbicidesMember2021-01-012021-03-310001755672dd:CropProtectionMemberdd:HerbicidesMember2020-01-012020-03-310001755672dd:InsecticidesMemberdd:CropProtectionMember2021-01-012021-03-310001755672dd:InsecticidesMemberdd:CropProtectionMember2020-01-012020-03-310001755672dd:FungicidesMemberdd:CropProtectionMember2021-01-012021-03-310001755672dd:FungicidesMemberdd:CropProtectionMember2020-01-012020-03-310001755672dd:CropProtectionMemberdd:OtherMember2021-01-012021-03-310001755672dd:CropProtectionMemberdd:OtherMember2020-01-012020-03-310001755672dd:CropProtectionMember2021-01-012021-03-310001755672dd:CropProtectionMember2020-01-012020-03-310001755672dei:LocationDomain2021-01-012021-03-310001755672srt:NorthAmericaMemberdd:SeedMember2021-01-012021-03-310001755672srt:NorthAmericaMemberdd:SeedMember2020-01-012020-03-310001755672us-gaap:EMEAMemberdd:SeedMember2021-01-012021-03-310001755672us-gaap:EMEAMemberdd:SeedMember2020-01-012020-03-310001755672srt:LatinAmericaMemberdd:SeedMember2021-01-012021-03-310001755672srt:LatinAmericaMemberdd:SeedMember2020-01-012020-03-310001755672srt:AsiaPacificMemberdd:SeedMember2021-01-012021-03-310001755672srt:AsiaPacificMemberdd:SeedMember2020-01-012020-03-310001755672srt:NorthAmericaMemberdd:CropProtectionMember2021-01-012021-03-310001755672srt:NorthAmericaMemberdd:CropProtectionMember2020-01-012020-03-310001755672us-gaap:EMEAMemberdd:CropProtectionMember2021-01-012021-03-310001755672us-gaap:EMEAMemberdd:CropProtectionMember2020-01-012020-03-310001755672srt:LatinAmericaMemberdd:CropProtectionMember2021-01-012021-03-310001755672srt:LatinAmericaMemberdd:CropProtectionMember2020-01-012020-03-310001755672srt:AsiaPacificMemberdd:CropProtectionMember2021-01-012021-03-310001755672srt:AsiaPacificMemberdd:CropProtectionMember2020-01-012020-03-310001755672srt:MinimumMemberdd:A2021RestructuringActionsDomain2021-03-310001755672dd:A2021RestructuringActionsDomainsrt:MaximumMember2021-03-310001755672srt:MinimumMemberdd:A2021RestructuringActionsDomainus-gaap:EmployeeSeveranceMember2021-03-310001755672dd:A2021RestructuringActionsDomainsrt:MaximumMemberus-gaap:EmployeeSeveranceMember2021-03-310001755672srt:MinimumMemberdd:A2021RestructuringActionsDomaindd:AssetRelatedChargesMember2021-03-310001755672dd:A2021RestructuringActionsDomainsrt:MaximumMemberdd:AssetRelatedChargesMember2021-03-310001755672srt:MinimumMemberdd:A2021RestructuringActionsDomainus-gaap:AssetRetirementObligationCostsMember2021-03-310001755672dd:A2021RestructuringActionsDomainsrt:MaximumMemberus-gaap:AssetRetirementObligationCostsMember2021-03-310001755672srt:MinimumMemberdd:A2021RestructuringActionsDomainus-gaap:ContractTerminationMember2021-03-310001755672dd:A2021RestructuringActionsDomainus-gaap:ContractTerminationMembersrt:MaximumMember2021-03-310001755672dd:A2021RestructuringActionsDomaindd:SeedMember2021-01-012021-03-310001755672dd:A2021RestructuringActionsDomaindd:CropProtectionMember2021-01-012021-03-310001755672us-gaap:CorporateMemberdd:A2021RestructuringActionsDomain2021-01-012021-03-310001755672dd:A2021RestructuringActionsDomain2021-01-012021-03-310001755672dd:A2021RestructuringActionsDomainus-gaap:EmployeeSeveranceMember2020-12-310001755672dd:A2021RestructuringActionsDomaindd:AssetRelatedChargesMember2020-12-310001755672dd:A2021RestructuringActionsDomaindd:CostsRelatedToContractTerminationMember2020-12-310001755672dd:A2021RestructuringActionsDomain2020-12-310001755672dd:A2021RestructuringActionsDomainus-gaap:EmployeeSeveranceMember2021-01-012021-03-310001755672dd:A2021RestructuringActionsDomaindd:AssetRelatedChargesMember2021-01-012021-03-310001755672dd:A2021RestructuringActionsDomaindd:CostsRelatedToContractTerminationMember2021-01-012021-03-310001755672dd:A2021RestructuringActionsDomainus-gaap:EmployeeSeveranceMember2021-03-310001755672dd:A2021RestructuringActionsDomaindd:AssetRelatedChargesMember2021-03-310001755672dd:A2021RestructuringActionsDomaindd:CostsRelatedToContractTerminationMember2021-03-310001755672dd:A2021RestructuringActionsDomain2021-03-310001755672dd:ExecutetoWinProductivityProgramDomain2020-01-012021-03-310001755672dd:ExecutetoWinProductivityProgramDomaindd:AssetRelatedChargesMember2020-01-012021-03-310001755672dd:ExecutetoWinProductivityProgramDomainus-gaap:EmployeeSeveranceMember2020-01-012021-03-310001755672dd:ExecutetoWinProductivityProgramDomain2021-01-012021-03-310001755672dd:ExecutetoWinProductivityProgramDomaindd:SeedMember2021-01-012021-03-310001755672dd:ExecutetoWinProductivityProgramDomaindd:SeedMember2020-01-012020-03-310001755672dd:ExecutetoWinProductivityProgramDomaindd:CropProtectionMember2021-01-012021-03-310001755672dd:ExecutetoWinProductivityProgramDomaindd:CropProtectionMember2020-01-012020-03-310001755672dd:ExecutetoWinProductivityProgramDomainus-gaap:CorporateNonSegmentMember2021-01-012021-03-310001755672dd:ExecutetoWinProductivityProgramDomainus-gaap:CorporateNonSegmentMember2020-01-012020-03-310001755672dd:ExecutetoWinProductivityProgramDomain2020-01-012020-03-310001755672dd:ExecutetoWinProductivityProgramDomainus-gaap:EmployeeSeveranceMember2021-01-012021-03-310001755672dd:ExecutetoWinProductivityProgramDomainus-gaap:EmployeeSeveranceMember2020-01-012020-03-310001755672dd:ExecutetoWinProductivityProgramDomaindd:AssetRelatedChargesMember2021-01-012021-03-310001755672dd:ExecutetoWinProductivityProgramDomaindd:AssetRelatedChargesMember2020-01-012020-03-310001755672dd:ExecutetoWinProductivityProgramDomainus-gaap:EmployeeSeveranceMember2020-12-310001755672dd:ExecutetoWinProductivityProgramDomaindd:AssetRelatedChargesMember2020-12-310001755672dd:ExecutetoWinProductivityProgramDomain2020-12-310001755672dd:ExecutetoWinProductivityProgramDomainus-gaap:EmployeeSeveranceMember2021-03-310001755672dd:ExecutetoWinProductivityProgramDomaindd:AssetRelatedChargesMember2021-03-310001755672dd:ExecutetoWinProductivityProgramDomain2021-03-310001755672dd:ExecutetoWinProductivityProgramDomainsrt:MinimumMember2021-01-012021-03-310001755672dd:ExecutetoWinProductivityProgramDomainsrt:MaximumMember2021-01-012021-03-310001755672dd:OtherAssetRelatedMember2021-01-012021-03-310001755672dd:OtherAssetRelatedMember2020-01-012020-03-310001755672dd:CropProtectionMemberus-gaap:MaterialReconcilingItemsMember2021-01-012021-03-310001755672dd:ArgentinePesoDevaluationMemberdd:HedgingProgramMember2021-01-012021-03-310001755672dd:ArgentinePesoDevaluationMemberdd:HedgingProgramMember2020-01-012020-03-310001755672srt:SubsidiariesMember2021-01-012021-03-310001755672srt:SubsidiariesMember2020-01-012020-03-310001755672dd:HedgingProgramMember2021-01-012021-03-310001755672dd:HedgingProgramMember2020-01-012020-03-310001755672us-gaap:OtherCurrentAssetsMember2021-03-310001755672us-gaap:OtherCurrentAssetsMember2020-12-310001755672us-gaap:OtherCurrentAssetsMember2020-03-310001755672dd:FactoringAgreementMember2021-01-012021-03-310001755672dd:FactoringAgreementMember2020-01-012020-03-310001755672dd:FactoringAgreementMember2021-03-310001755672dd:FactoringAgreementMember2020-12-310001755672dd:FactoringAgreementMember2020-03-310001755672dd:GermplasmMember2021-03-310001755672dd:GermplasmMember2020-12-310001755672dd:GermplasmMember2020-03-310001755672us-gaap:CustomerRelatedIntangibleAssetsMember2021-03-310001755672us-gaap:CustomerRelatedIntangibleAssetsMember2020-12-310001755672us-gaap:CustomerRelatedIntangibleAssetsMember2020-03-310001755672us-gaap:DevelopedTechnologyRightsMember2021-03-310001755672us-gaap:DevelopedTechnologyRightsMember2020-12-310001755672us-gaap:DevelopedTechnologyRightsMember2020-03-310001755672us-gaap:TrademarksAndTradeNamesMember2021-03-310001755672us-gaap:TrademarksAndTradeNamesMember2020-12-310001755672us-gaap:TrademarksAndTradeNamesMember2020-03-310001755672dd:FavorableSupplyContractMember2021-03-310001755672dd:FavorableSupplyContractMember2020-12-310001755672dd:FavorableSupplyContractMember2020-03-310001755672us-gaap:OtherIntangibleAssetsMember2021-03-310001755672us-gaap:OtherIntangibleAssetsMember2020-12-310001755672us-gaap:OtherIntangibleAssetsMember2020-03-310001755672us-gaap:InProcessResearchAndDevelopmentMember2021-03-310001755672us-gaap:InProcessResearchAndDevelopmentMember2020-12-310001755672us-gaap:InProcessResearchAndDevelopmentMember2020-03-310001755672us-gaap:TradeNamesMember2020-03-310001755672us-gaap:SegmentContinuingOperationsMember2021-03-310001755672us-gaap:CommercialPaperMember2021-03-310001755672us-gaap:CommercialPaperMember2020-12-310001755672us-gaap:CommercialPaperMember2020-03-310001755672us-gaap:SecuritiesSoldUnderAgreementsToRepurchaseMemberus-gaap:RepurchaseAgreementsMember2021-03-310001755672us-gaap:SecuritiesSoldUnderAgreementsToRepurchaseMemberus-gaap:RepurchaseAgreementsMember2020-12-310001755672us-gaap:SecuritiesSoldUnderAgreementsToRepurchaseMemberus-gaap:RepurchaseAgreementsMember2020-03-310001755672dd:OtherloansvariouscurrenciesMember2021-03-310001755672dd:OtherloansvariouscurrenciesMember2020-12-310001755672dd:OtherloansvariouscurrenciesMember2020-03-310001755672us-gaap:FairValueInputsLevel2Member2021-03-310001755672us-gaap:FairValueInputsLevel2Member2020-12-310001755672us-gaap:FairValueInputsLevel2Member2020-03-310001755672us-gaap:SecuritiesSoldUnderAgreementsToRepurchaseMember2021-02-090001755672dd:AccountsandNotesReceivableMemberus-gaap:SecuritiesSoldUnderAgreementsToRepurchaseMemberus-gaap:RepurchaseAgreementsMember2021-03-310001755672dd:RevolvingCreditFacilitiesdue2024Member2018-11-130001755672srt:ScenarioForecastMemberdd:RevolvingCreditFacilitiesdue2024Member2018-11-132023-11-130001755672dd:RevolvingCreditFacilitiesdue2022Member2018-11-130001755672dd:RevolvingCreditFacilitiesdue2022Membersrt:ScenarioForecastMember2018-11-132021-11-130001755672dd:RevolvingCreditFacilitiesdue2022Member2018-11-130001755672dd:RevolvingCreditFacilitiesdue2022Member2020-03-310001755672dd:RevolvingCreditFacilitiesdue2022Member2021-03-310001755672dd:NotesMaturing2030Domainus-gaap:LoansPayableMember2021-03-310001755672dd:FactoringAgreementMember2021-03-310001755672dd:FactoringAgreementMember2020-12-310001755672dd:AgreementswithlenderstoprovidefinancingforselectcustomersMember2021-03-310001755672dd:AgreementswithlenderstoprovidefinancingforselectcustomersMember2020-12-310001755672dd:AgreementswithlenderstoprovidefinancingforselectcustomersMember2020-03-310001755672dd:CortevaMemberdd:DuPontdeNemoursMemberdd:PFOAMattersMultiDistrictLitigationMember2017-04-012017-06-30dd:lawsuits0001755672dd:PFOAMattersMultiDistrictLitigationMember2017-12-310001755672dd:PFOAMattersDrinkingWaterActionsMemberdd:ScheduledfortrialMemberdd:PostMDLSettlementPFOAPersonalInjuryClaimsDomain2021-03-310001755672srt:MaximumMemberdd:PFASMember2021-01-012021-03-310001755672srt:MaximumMemberdd:PFASMember2021-03-310001755672dd:CortevaMemberdd:PFASMemberdd:DuPontdeNemoursMember2021-03-310001755672dd:CortevaMembersrt:MaximumMemberdd:PFASMemberdd:DuPontdeNemoursMember2021-03-310001755672dd:DuPontdeNemoursMember2021-03-310001755672dd:DuPontdeNemoursMember2021-03-310001755672dd:CortevaMember2021-03-310001755672dd:ChemoursMemberdd:PFASMember2022-09-300001755672dd:CortevaMemberdd:PFASMemberdd:DuPontdeNemoursMember2022-09-300001755672dd:ChemoursMemberdd:PFASMember2028-09-300001755672dd:CortevaMemberdd:PFASMemberdd:DuPontdeNemoursMember2028-09-300001755672srt:MaximumMemberdd:ChemoursMemberdd:PFASMember2028-09-300001755672dd:CortevaMembersrt:MaximumMemberdd:PFASMemberdd:DuPontdeNemoursMember2028-09-300001755672dd:PFASMember2028-12-310001755672dd:ChemoursMemberdd:PFASMember2021-03-310001755672dd:DuPontdeNemoursMemberdd:DuPontdeNemoursMember2021-03-310001755672dd:CortevaMemberdd:DuPontdeNemoursMember2021-03-310001755672dd:CortevaMemberdd:PFASMember2021-03-310001755672dd:PFASMemberdd:DuPontdeNemoursMember2021-03-310001755672srt:MinimumMemberdd:PFASMember2021-03-310001755672srt:MinimumMemberdd:Once300millionthresholdismetMemberdd:PFASMember2021-03-310001755672dd:ChemoursMemberdd:PFOAMattersMember2021-03-310001755672dd:PFOAMattersDrinkingWaterActionsMember2004-01-012004-12-310001755672dd:PFOAMattersDrinkingWaterActionsMember2012-01-010001755672dd:PFOAMattersDrinkingWaterActionsMember2004-12-310001755672dd:PFOAMattersDrinkingWaterActionsMember2012-01-012020-09-300001755672dd:PFOAMattersDrinkingWaterActionsMember2021-03-310001755672dd:PFOAMattersMultiDistrictLitigationMember2021-03-310001755672dd:PFOAMattersMultiDistrictLitigationMember2017-10-012017-12-310001755672dd:PFOAMattersDrinkingWaterActionsMemberdd:CompensatorydamagesMemberdd:PostMDLSettlementPFOAPersonalInjuryClaimsDomain2021-01-012021-03-310001755672dd:PFOAMattersDrinkingWaterActionsMemberdd:LossofconsortiumMemberdd:PostMDLSettlementPFOAPersonalInjuryClaimsDomain2021-01-012021-03-310001755672us-gaap:SettledLitigationMemberdd:PFOAMattersDrinkingWaterActionsMemberdd:PostMDLSettlementPFOAPersonalInjuryClaimsDomain2021-01-012021-03-310001755672dd:MDLSettlementMember2021-01-012021-03-310001755672dd:ChemoursContributionToMDLSettlementMember2021-01-012021-03-310001755672dd:DuPontDeNemoursAndCortevaContributionToMDLSettlementMember2021-01-012021-03-310001755672dd:PFOAMattersDrinkingWaterActionsMemberstpr:NY2021-03-310001755672dd:PFOAMattersDrinkingWaterActionsMemberstpr:NJ2021-03-310001755672dd:NaturalResourcesDamagesMemberstpr:NJ2021-03-310001755672dd:PFOAMattersDrinkingWaterActionsMemberstpr:OH2021-03-310001755672dd:FirefightingFoamMember2021-03-310001755672dd:FirefightingFoamMemberdd:PersonalinjurycasesMember2021-03-310001755672stpr:NCdd:PFOAMattersDrinkingWaterActionsMember2021-01-012021-03-310001755672dd:SuperfundSitesMember2021-03-310001755672dd:ChemoursrelatedobligationsubjecttoindemnificationMember2021-03-310001755672us-gaap:SegmentDiscontinuedOperationsMember2021-03-310001755672dd:OtherdiscontinuedordivestedbusinessobligationsMember2021-03-310001755672dd:EnvironmentalremediationliabilitiesprimarilyrelatedtoDuPontsubjecttoindemnityfromDuPontMember2021-03-310001755672dd:NotsubjecttoindemnificationMember2021-03-310001755672dd:ChemoursMemberdd:SuperfundSitesMemberus-gaap:IndemnificationGuaranteeMember2021-03-310001755672dd:PerformanceChemicalsMember2021-03-310001755672dd:NaturalResourcesDamagesMemberdd:AlabamaWaterUtilityMember2021-03-310001755672dd:FactoringAgreementMember2020-03-3100017556722019-06-260001755672dd:CortevaMember2019-06-260001755672dd:CortevaMember2021-01-012021-03-310001755672dd:CortevaMember2020-01-012020-03-310001755672dd:EIDMemberdd:CortevaMember2021-01-012021-03-310001755672dd:EIDMemberdd:A4.50SeriesPreferredStockMember2021-03-310001755672dd:EIDMemberdd:A3.50SeriesPreferredStockMember2021-03-310001755672us-gaap:AccumulatedTranslationAdjustmentMember2019-12-310001755672us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2019-12-310001755672us-gaap:PensionPlansDefinedBenefitMember2019-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-12-310001755672us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-12-310001755672us-gaap:AccumulatedTranslationAdjustmentMember2020-01-012020-03-310001755672us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2020-01-012020-03-310001755672us-gaap:PensionPlansDefinedBenefitMember2020-01-012020-03-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-01-012020-03-310001755672us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-01-012020-03-310001755672us-gaap:AccumulatedTranslationAdjustmentMember2020-03-310001755672us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2020-03-310001755672us-gaap:PensionPlansDefinedBenefitMember2020-03-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-03-310001755672us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-03-310001755672us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310001755672us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2020-12-310001755672us-gaap:PensionPlansDefinedBenefitMember2020-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-12-310001755672us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-12-310001755672us-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-03-310001755672us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-01-012021-03-310001755672us-gaap:PensionPlansDefinedBenefitMember2021-01-012021-03-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-01-012021-03-310001755672us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-01-012021-03-310001755672us-gaap:AccumulatedTranslationAdjustmentMember2021-03-310001755672us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-03-310001755672us-gaap:PensionPlansDefinedBenefitMember2021-03-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-03-310001755672us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-03-310001755672us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMemberus-gaap:PensionPlansDefinedBenefitMember2021-01-012021-03-310001755672us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMemberus-gaap:PensionPlansDefinedBenefitMember2020-01-012020-03-310001755672us-gaap:PensionPlansDefinedBenefitMemberdd:AccumulatedDefinedBenefitPlansAdjustmentSettlementGainLossMember2021-01-012021-03-310001755672us-gaap:PensionPlansDefinedBenefitMemberdd:AccumulatedDefinedBenefitPlansAdjustmentSettlementGainLossMember2020-01-012020-03-310001755672us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:PensionPlansDefinedBenefitMember2021-01-012021-03-310001755672us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:PensionPlansDefinedBenefitMember2020-01-012020-03-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2021-01-012021-03-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2020-01-012020-03-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-01-012021-03-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-01-012020-03-310001755672dd:EIDMemberdd:A4.50SeriesPreferredStockMember2020-12-310001755672dd:EIDMemberdd:A4.50SeriesPreferredStockMember2020-03-310001755672dd:EIDMemberdd:A3.50SeriesPreferredStockMember2020-12-310001755672dd:EIDMemberdd:A3.50SeriesPreferredStockMember2020-03-310001755672us-gaap:CashEquivalentsMember2021-03-310001755672us-gaap:CashEquivalentsMember2020-12-310001755672us-gaap:CashEquivalentsMember2020-03-310001755672dd:MarketableSecuritiesMember2021-03-310001755672dd:MarketableSecuritiesMember2020-12-310001755672dd:MarketableSecuritiesMember2020-03-310001755672us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2021-03-310001755672us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2020-12-310001755672us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2020-03-310001755672us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CommodityContractMember2021-03-310001755672us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CommodityContractMember2020-12-310001755672us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CommodityContractMember2020-03-310001755672us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2021-03-310001755672us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2020-12-310001755672us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2020-03-310001755672us-gaap:NondesignatedMemberus-gaap:CommodityContractMember2021-03-310001755672us-gaap:NondesignatedMemberus-gaap:CommodityContractMember2020-12-310001755672us-gaap:NondesignatedMemberus-gaap:CommodityContractMember2020-03-310001755672us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CommodityContractMember2021-01-012021-03-310001755672us-gaap:CommodityContractMember2021-01-012021-03-310001755672us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CommodityContractMember2019-12-310001755672us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CommodityContractMember2020-01-012020-03-310001755672us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2021-01-012021-03-310001755672us-gaap:ForeignExchangeContractMember2021-01-012021-03-310001755672us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2019-12-310001755672us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2020-01-012020-03-31iso4217:EUR0001755672us-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMember2021-03-310001755672us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMember2021-03-310001755672us-gaap:OtherCurrentAssetsMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2021-03-310001755672us-gaap:DesignatedAsHedgingInstrumentMemberdd:AccruedandOtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMember2021-03-310001755672dd:AccruedandOtherCurrentLiabilitiesMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2021-03-310001755672us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMember2020-12-310001755672us-gaap:OtherCurrentAssetsMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2020-12-310001755672us-gaap:DesignatedAsHedgingInstrumentMemberdd:AccruedandOtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMember2020-12-310001755672dd:AccruedandOtherCurrentLiabilitiesMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2020-12-310001755672us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMember2020-03-310001755672us-gaap:OtherCurrentAssetsMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2020-03-310001755672dd:AccruedandOtherCurrentLiabilitiesMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2020-03-310001755672us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMember2021-01-012021-03-310001755672us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMember2020-01-012020-03-310001755672us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2021-01-012021-03-310001755672us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2020-01-012020-03-310001755672us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CommodityContractMemberus-gaap:CashFlowHedgingMember2021-01-012021-03-310001755672us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CommodityContractMemberus-gaap:CashFlowHedgingMember2020-01-012020-03-310001755672us-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-03-310001755672us-gaap:DesignatedAsHedgingInstrumentMember2020-01-012020-03-310001755672us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CostOfSalesMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2021-01-012021-03-310001755672us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CostOfSalesMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeContractMember2020-01-012020-03-310001755672us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CostOfSalesMemberus-gaap:CommodityContractMemberus-gaap:CashFlowHedgingMember2021-01-012021-03-310001755672us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CostOfSalesMemberus-gaap:CommodityContractMemberus-gaap:CashFlowHedgingMember2020-01-012020-03-310001755672us-gaap:NondesignatedMemberus-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMember2021-01-012021-03-310001755672us-gaap:NondesignatedMemberus-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMember2020-01-012020-03-310001755672us-gaap:NondesignatedMemberus-gaap:CostOfSalesMemberus-gaap:ForeignExchangeContractMember2021-01-012021-03-310001755672us-gaap:NondesignatedMemberus-gaap:CostOfSalesMemberus-gaap:ForeignExchangeContractMember2020-01-012020-03-310001755672us-gaap:NondesignatedMemberus-gaap:CostOfSalesMemberus-gaap:CommodityContractMember2021-01-012021-03-310001755672us-gaap:NondesignatedMemberus-gaap:CostOfSalesMemberus-gaap:CommodityContractMember2020-01-012020-03-310001755672us-gaap:NondesignatedMember2021-01-012021-03-310001755672us-gaap:NondesignatedMember2020-01-012020-03-310001755672us-gaap:AvailableforsaleSecuritiesMember2021-01-012021-03-310001755672us-gaap:USTreasurySecuritiesMember2021-03-310001755672us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001755672us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2021-03-310001755672us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2021-03-310001755672us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-03-310001755672us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001755672us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2020-12-310001755672us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2020-12-310001755672us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-12-310001755672us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-03-310001755672us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2020-03-310001755672dd:SeedMember2021-03-310001755672dd:CropProtectionMember2021-03-310001755672dd:SeedMember2020-03-310001755672dd:CropProtectionMember2020-03-310001755672dd:SeedMember2020-12-310001755672dd:CropProtectionMember2020-12-310001755672us-gaap:MaterialReconcilingItemsMember2021-01-012021-03-310001755672us-gaap:MaterialReconcilingItemsMember2020-01-012020-03-310001755672dd:SeedMemberus-gaap:MaterialReconcilingItemsMember2021-01-012021-03-310001755672us-gaap:CorporateNonSegmentMemberus-gaap:MaterialReconcilingItemsMember2021-01-012021-03-310001755672dd:SeedMemberus-gaap:MaterialReconcilingItemsMember2020-01-012020-03-310001755672dd:CropProtectionMemberus-gaap:MaterialReconcilingItemsMember2020-01-012020-03-310001755672us-gaap:CorporateNonSegmentMemberus-gaap:MaterialReconcilingItemsMember2020-01-012020-03-310001755672dd:CropProtectionMemberdd:LaPorteMemberus-gaap:MaterialReconcilingItemsMember2020-01-012020-03-310001755672dd:LaPorteMemberus-gaap:MaterialReconcilingItemsMember2020-01-012020-03-310001755672dd:EIDMember2020-01-012020-03-310001755672dd:EIDMemberus-gaap:PensionPlansDefinedBenefitMember2021-01-012021-03-310001755672dd:EIDMemberus-gaap:PensionPlansDefinedBenefitMember2020-01-012020-03-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberdd:EIDMember2021-01-012021-03-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberdd:EIDMember2020-01-012020-03-310001755672dd:EIDMember2021-03-310001755672dd:EIDMember2020-12-310001755672dd:EIDMember2020-03-310001755672dd:EIDMemberdd:TotalcompanyMember2021-01-012021-03-310001755672dd:EIDMemberdd:TotalcompanyMember2020-01-012020-03-310001755672dd:EIDMember2019-12-310001755672dd:EIDMemberus-gaap:PreferredStockMember2019-12-310001755672dd:EIDMemberus-gaap:CommonStockMember2019-12-310001755672dd:EIDMemberus-gaap:AdditionalPaidInCapitalMember2019-12-310001755672dd:EIDMemberus-gaap:RetainedEarningsMember2019-12-310001755672dd:EIDMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001755672dd:EIDMemberus-gaap:NoncontrollingInterestMember2019-12-310001755672dd:EIDMemberus-gaap:RetainedEarningsMember2020-01-012020-03-310001755672dd:EIDMemberus-gaap:NoncontrollingInterestMember2020-01-012020-03-310001755672dd:EIDMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310001755672dd:EIDMemberus-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-310001755672dd:EIDMemberus-gaap:PreferredStockMember2020-03-310001755672dd:EIDMemberus-gaap:CommonStockMember2020-03-310001755672dd:EIDMemberus-gaap:AdditionalPaidInCapitalMember2020-03-310001755672dd:EIDMemberus-gaap:RetainedEarningsMember2020-03-310001755672dd:EIDMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-310001755672dd:EIDMemberus-gaap:NoncontrollingInterestMember2020-03-310001755672dd:EIDMemberus-gaap:PreferredStockMember2020-12-310001755672dd:EIDMemberus-gaap:CommonStockMember2020-12-310001755672dd:EIDMemberus-gaap:AdditionalPaidInCapitalMember2020-12-310001755672dd:EIDMemberus-gaap:RetainedEarningsMember2020-12-310001755672dd:EIDMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001755672dd:EIDMemberus-gaap:NoncontrollingInterestMember2020-12-310001755672dd:EIDMemberus-gaap:RetainedEarningsMember2021-01-012021-03-310001755672dd:EIDMemberus-gaap:NoncontrollingInterestMember2021-01-012021-03-310001755672dd:EIDMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001755672dd:EIDMemberus-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001755672dd:EIDMemberus-gaap:PreferredStockMember2021-03-310001755672dd:EIDMemberus-gaap:CommonStockMember2021-03-310001755672dd:EIDMemberus-gaap:AdditionalPaidInCapitalMember2021-03-310001755672dd:EIDMemberus-gaap:RetainedEarningsMember2021-03-310001755672dd:EIDMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001755672dd:EIDMemberus-gaap:NoncontrollingInterestMember2021-03-310001755672dd:EIDMemberdd:A4.50SeriesPreferredStockMember2020-01-012020-03-310001755672dd:EIDMemberdd:A3.50SeriesPreferredStockMember2020-01-012020-03-310001755672dd:CortevaMember2021-03-310001755672dd:EIDMemberdd:CortevaMember2021-03-310001755672dd:EIDMemberdd:CortevaMember2020-03-310001755672dd:EIDMemberdd:CortevaMember2021-01-012021-03-310001755672dd:EIDMemberdd:CortevaMember2020-01-012020-03-310001755672dd:EIDMemberdd:CortevaMemberdd:AccruedandOtherCurrentLiabilitiesMember2021-03-310001755672dd:EIDMemberdd:CortevaMemberus-gaap:OtherNoncurrentLiabilitiesMember2021-03-310001755672dd:EIDMemberdd:CortevaMemberdd:AccruedandOtherCurrentLiabilitiesMember2020-12-310001755672dd:EIDMemberdd:CortevaMemberdd:AccruedandOtherCurrentLiabilitiesMember2020-03-310001755672dd:EIDMemberdd:CortevaMemberus-gaap:OtherNoncurrentLiabilitiesMember2020-03-310001755672dd:EIDMemberdd:CortevaMember2020-12-310001755672dd:EIDMemberdd:CortevaMemberus-gaap:OtherNoncurrentLiabilitiesMember2020-12-310001755672dd:EIDMemberus-gaap:MaterialReconcilingItemsMember2021-01-012021-03-310001755672dd:EIDMemberus-gaap:MaterialReconcilingItemsMember2020-01-012020-03-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549 
FORM 10-Q
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2021
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number 001-38710
Corteva, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware   82-4979096
(State or other Jurisdiction of Incorporation or Organization)   (I.R.S. Employer Identification No.)
974 Centre Road, Wilmington, Delaware 19805   (302) 485-3000
(Address of Principal Executive Offices) (Zip Code) (Registrant’s Telephone Number, including area code)
Commission File Number 1-815
E. I. du Pont de Nemours and Company
(Exact Name of Registrant as Specified in Its Charter)
Delaware   51-0014090
(State or other Jurisdiction of Incorporation or Organization)   (I.R.S. Employer Identification No.)
974 Centre Road, Wilmington, Delaware 19805   (302) 485-3000
(Address of Principal Executive Offices) (Zip Code) (Registrant’s Telephone Number, including area code)


Securities registered pursuant to Section 12(b) of the Act for Corteva, Inc.:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.01 per share CTVA New York Stock Exchange

Securities registered pursuant to Section 12(b) of the Act for E. I. du Pont de Nemours and Company:
Title of each class Trading Symbol(s) Name of each exchange on which registered
$3.50 Series Preferred Stock CTAPrA New York Stock Exchange
$4.50 Series Preferred Stock CTAPrB New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  
Corteva, Inc.                                          Yes  x   No  o
E. I. du Pont de Nemours and Company                          Yes  x   No  o

 Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.)  
Corteva, Inc.                                       Yes  x   No  o
E. I. du Pont de Nemours and Company                           Yes  x   No  o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.  See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Corteva, Inc.
Large Accelerated Filer x
Accelerated Filer o
Non-Accelerated Filer o
Smaller reporting company o
Emerging growth company o
E. I. du Pont de Nemours and Company
Large Accelerated Filer o
Accelerated Filer o
Non-Accelerated Filer
x

Smaller reporting company o
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 
Corteva, Inc.                                                  ☐
E. I. du Pont de Nemours and Company                                   ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). 
Corteva, Inc.                                          Yes  ☐   No  x
E. I. du Pont de Nemours and Company                          Yes  ☐   No  x

Corteva, Inc. had 737,101,000 shares of common stock, par value $0.01 per share, outstanding at April 30, 2021.
E. I. du Pont de Nemours and Company had 200 shares of common stock, par value $0.30 per share, outstanding at April 30, 2021, all of which are held by Corteva, Inc.    

E. I. du Pont de Nemours and Company meets the conditions set forth in General Instruction H(1)(a) and (b) of Form 10-Q (as modified by a grant of no-action relief dated February 12, 2018) and is therefore filing this form with reduced disclosure format.

CORTEVA, INC.
E. I. DU PONT DE NEMOURS AND COMPANY

Table of Contents
    Page
 
     
 
 
3
4
 
5
 
6
7
 
8
     
38
 
38
39
39
41
 
42
 
44
44
47
 
50
 
52
     
52
53
     
 
     
54
56
57
58
59
 
59
 
60
61

1
Explanatory Note

Corteva owns 100% of the outstanding common stock of EID (defined below), and EID owns, directly or indirectly, 100% of DAS (defined below). EID is a subsidiary of Corteva, Inc. and continues to be a reporting company, subject to the requirements of the Securities Exchange Act of 1934, as amended.

Unless otherwise indicated or the context otherwise requires, references in this Quarterly Report on Form 10-Q to:

    • "Corteva" or "the company" refers to Corteva, Inc. and its consolidated subsidiaries (including EID);
• "EID" refers to E. I. du Pont de Nemours and Company and its consolidated subsidiaries or E. I. du Pont de Nemours and Company excluding its consolidated subsidiaries, as the context may indicate;
    • "DowDuPont" refers to DowDuPont Inc., and its subsidiaries prior to the Separation of Corteva (defined below);
• "Historical Dow" refers to the Dow Chemical Company and its consolidated subsidiaries prior to the Internal Reorganization (defined below);
    • "Historical DuPont" refers to EID prior to the Internal Reorganization (defined below);
• "Internal Reorganizations" refers to the series of internal reorganization and realignment steps undertaken by Historical DuPont and Historical Dow to realign its business into three groups: agriculture, materials science and specialty products.  These steps include:
1.the April 1, 2019 transfer of the assets and liabilities aligned with EID’s material science businesses including EID’s ethylene and ethylene copolymers business, excluding its ethylene acrylic elastomers business, (“EID ECP”) to DowDuPont, which were ultimately conveyed by DowDuPont to Dow;
2.the May 1, 2019 distribution of EID legal entities containing the assets and liabilities of EID’s specialty products business (the “EID Specialty Products Entities”) to DowDuPont;
3.the May 2, 2019 conveyance of Historical Dow's agriculture business ("Dow Ag Entities") to EID; and
4.the May 31, 2019 contribution of EID to Corteva, Inc.  Refer to the company’s Annual Report on Form 10-K for the year ended December 31, 2020 for further information.
• "Dow Distribution" refers to the separation of DowDuPont's materials science business into a separate and independent public company, effective as of 5:00 pm ET on April 1, 2019, by way of a distribution of Dow Inc. through a pro rata dividend in-kind of all of the then-issued and outstanding shares of Dow’s common stock, par value $0.01 per share, to holders of DowDuPont's common stock, as of the close of business on March 21, 2019;
    • "Distributions" refers to the Dow Distribution and the Corteva Distribution;
• "Merger” refers to the all-stock merger of equals strategic combination between Historical Dow and Historical DuPont;
• "Merger Effectiveness Time” refers to August 31, 2017 at 11:59 pm ET;
    • "Dow" refers to Dow Inc. after the Dow Distribution;
    • "DuPont" refers to DuPont de Nemours, Inc. after the Separation of Corteva (on June 1, 2019, DowDuPont Inc. changed its registered name to DuPont de Nemours, Inc.);
    • "DAS" refers to the agriculture business of Historical Dow AgroSciences; and
• "Separation" or "Separation of Corteva" refers to June 1, 2019, when Corteva, Inc. became an independent, publicly
    traded company.

This Quarterly Report on Form 10-Q is a combined report being filed separately by Corteva, Inc. and EID.  The information in this Quarterly Report on Form 10-Q is equally applicable to Corteva, Inc. and EID, except where otherwise indicated.

The separate EID financial statements and footnotes for areas that differ from Corteva, are included within this Quarterly Report on Form 10-Q and begin on page 61. Footnotes of EID that are identical to that of Corteva are cross-referenced accordingly.
2
PART I.  FINANCIAL INFORMATION 

Item 1.CONSOLIDATED FINANCIAL STATEMENTS

Corteva, Inc.
Consolidated Statements of Operations (Unaudited)
(In millions, except per share amounts) Three Months Ended
March 31,
2021 2020
Net sales $ 4,178  $ 3,956 
Cost of goods sold
2,420  2,269 
Research and development expense
281  280 
Selling, general and administrative expenses
733  757 
Amortization of intangibles
183  163 
Restructuring and asset related charges - net
100  70 
Other income - net 337  1 
Interest expense
7  10 
Income from continuing operations before income taxes 791  408 
Provision for income taxes on continuing operations 178  127 
Income from continuing operations after income taxes 613  281 
(Loss) income from discontinued operations after income taxes (10) 1 
Net income 603  282 
Net income attributable to noncontrolling interests 3  10 
Net income attributable to Corteva $ 600  $ 272 
Basic earnings per share of common stock:
Basic earnings per share of common stock from continuing operations $ 0.82  $ 0.36 
Basic loss per share of common stock from discontinued operations (0.01) — 
Basic earnings per share of common stock $ 0.81  $ 0.36 
Diluted earnings per share of common stock:
Diluted earnings per share of common stock from continuing operations $ 0.81  $ 0.36 
Diluted loss per share of common stock from discontinued operations (0.01) — 
Diluted earnings per share of common stock $ 0.80  $ 0.36 

See Notes to the interim Consolidated Financial Statements beginning on page 8.
3
Corteva, Inc.
Consolidated Statements of Comprehensive (Loss) Income (Unaudited)
(In millions) Three Months Ended
March 31,
2021 2020
Net income $ 603  $ 282 
Other comprehensive income (loss) - net of tax:
Cumulative translation adjustments
(403) (672)
Adjustments to pension benefit plans
8  — 
Adjustments to other benefit plans
(157) 3 
Unrealized gain on investments 10  — 
Derivative instruments
65  6 
Total other comprehensive loss (477) (663)
Comprehensive income (loss) 126  (381)
Comprehensive income attributable to noncontrolling interests - net of tax 3  10 
Comprehensive income (loss) attributable to Corteva $ 123  $ (391)

See Notes to the interim Consolidated Financial Statements beginning on page 8.

4
Corteva, Inc.
Condensed Consolidated Balance Sheets (Unaudited)
(In millions, except share amounts) March 31, 2021 December 31, 2020 March 31, 2020
Assets    
Current assets    
Cash and cash equivalents $ 2,404  $ 3,526  $ 1,963 
Marketable securities 114  269  10 
Accounts and notes receivable - net 6,792  4,926  6,775 
Inventories 4,321  4,882  4,401 
Other current assets 1,405  1,165  1,530 
Total current assets 15,036  14,768  14,679 
Investment in nonconsolidated affiliates 64  66  64 
Property, plant and equipment - net of accumulated depreciation (March 31, 2021 - $3,874; December 31, 2020 - $3,857; March 31, 2020 - $3,406) 4,299  4,396  4,358 
Goodwill 10,146  10,269  10,027 
Other intangible assets 10,584  10,747  11,241 
Deferred income taxes 433  464  273 
Other assets 1,987  1,939  2,336 
Total Assets $ 42,549  $ 42,649  $ 42,978 
Liabilities and Equity    
Current liabilities    
Short-term borrowings and finance lease obligations $ 1,250  $ 3  $ 1,996 
Accounts payable 3,098  3,615  3,021 
Income taxes payable 165  123  143 
Deferred revenue 2,247  2,662  1,996 
Accrued and other current liabilities 2,239  2,145  2,043 
Total current liabilities 8,999  8,548  9,199 
Long-Term Debt 1,102  1,102  614 
Other Noncurrent Liabilities
Deferred income tax liabilities 902  893  911 
Pension and other post employment benefits - noncurrent 4,954  5,176  6,186 
Other noncurrent obligations 1,814  1,867  1,989 
Total noncurrent liabilities 8,772  9,038  9,700 
Commitments and contingent liabilities
Stockholders’ equity    
Common stock, $0.01 par value; 1,666,667,000 shares authorized;
issued at March 31, 2021 - 738,321,000; December 31, 2020 - 743,458,000; and March 31, 2020 - 748,369,000 		7  7  7 
Additional paid-in capital 27,630  27,707  27,906 
Retained earnings / (accumulated deficit) 268  —  (155)
Accumulated other comprehensive loss (3,367) (2,890) (3,933)
Total Corteva stockholders’ equity 24,538  24,824  23,825 
Noncontrolling interests 240  239  254 
Total equity 24,778  25,063  24,079 
Total Liabilities and Equity $ 42,549  $ 42,649  $ 42,978 
See Notes to the interim Consolidated Financial Statements beginning on page 8.
5
Corteva, Inc.
Consolidated Statements of Cash Flows (Unaudited)
(In millions) Three Months Ended
March 31,
2021 2020
Operating activities
Net income $ 603  $ 282 
Adjustments to reconcile net income to cash used for operating activities:
Depreciation and amortization 304  283 
Provision for deferred income tax 47  26 
Net periodic pension and OPEB benefit, net (318) (85)
Pension and OPEB contributions (84) (95)
Net loss on sales of property, businesses, consolidated companies and investments —  46 
Restructuring and asset related charges - net 100  70 
Other net loss 54  138 
Changes in assets and liabilities, net
Accounts and notes receivable (2,012) (1,685)
Inventories 467  398 
Accounts payable (448) (557)
Deferred revenue (401) (575)
Other assets and liabilities (262) (176)
Cash used for operating activities (1,950) (1,930)
Investing activities  
Capital expenditures (137) (128)
Proceeds from sales of property, businesses and consolidated companies - net of cash divested 20  11 
Purchases of investments (40) (67)
Proceeds from sales and maturities of investments 194  58 
Other investing activities - net (1) (4)
Cash provided by (used for) investing activities 36  (130)
Financing activities  
Net change in borrowings (less than 90 days) 828  1,619 
Proceeds from debt 419  875 
Payments on debt —  (1)
Repurchase of common stock (350) (50)
Proceeds from exercise of stock options 38  14 
Dividends paid to stockholders (97) (97)
Other financing activities (17) (16)
Cash provided by financing activities 821  2,344 
Effect of exchange rate changes on cash, cash equivalents and restricted cash (50) (117)
(Decrease)/increase in cash, cash equivalents and restricted cash (1,143) 167 
Cash, cash equivalents and restricted cash at beginning of period 3,873  2,173 
Cash, cash equivalents and restricted cash at end of period1
$ 2,730  $ 2,340 
1. See page 15 for reconciliation of cash and cash equivalents and restricted cash presented in interim Condensed Consolidated Balance Sheets to total cash, cash equivalents and restricted cash presented in the interim Consolidated Statements of Cash Flows.

See Notes to the interim Consolidated Financial Statements beginning on page 8.
6
Corteva, Inc.
Consolidated Statements of Equity (Unaudited)
(In millions, except per share amounts) Common Stock Additional Paid-in Capital "APIC" (Accumulated deficit) Retained Earnings Accumulated Other Comp (Loss) Income Treasury Stock Non-controlling Interests Total Equity
2020
Balance at January 1, 2020 $ 7  $ 27,997  $ (425) $ (3,270) $ —  $ 246  $ 24,555 
Net income
272  10  282 
Other comprehensive loss
(663) (663)
Common dividends ($.13 per share) (97) (97)
Issuance of Corteva stock 14  14 
Share-based compensation
2  2 
Repurchase of common stock (50) (50)
Other - net
40  (2) (2) 36 
Balance at March 31, 2020 $ 7  $ 27,906  $ (155) $ (3,933) $ —  $ 254  $ 24,079 
(In millions, except per share amounts) Common Stock Additional Paid-in Capital "APIC" (Accumulated deficit) Retained Earnings Accumulated Other Comp (Loss) Income Treasury Stock Non-controlling Interests Total Equity
2021
Balance at January 1, 2021 $ 7  $ 27,707  $ —  $ (2,890) $ —  $ 239  $ 25,063 
Net income
600  3  603 
Other comprehensive loss
(477) (477)
Common dividends ($0.13 per share)
(97) (97)
Issuance of Corteva stock
38  38 
Repurchase of common stock (18) (332) (350)
Other - net
(2) (2)
Balance at March 31, 2021 $ 7  $ 27,630  $ 268  $ (3,367) $ —  $ 240  $ 24,778 


See Notes to the interim Consolidated Financial Statements beginning on page 8.
7
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Corteva, Inc.
Notes to the Consolidated Financial Statements (Unaudited)


Table of Contents



8
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation
The accompanying unaudited interim Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") for interim financial information and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X.  In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the results for interim periods have been included.  Results for interim periods should not be considered indicative of results for a full year.  These interim Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and Notes thereto contained in the company’s Annual Report on Form 10-K for the year ended December 31, 2020, collectively referred to as the “2020 Annual Report.”  The interim Consolidated Financial Statements include the accounts of the company and all of its subsidiaries in which a controlling interest is maintained.

Certain reclassifications of prior year's data have been made to conform to current year's presentation.

During the first quarter 2020, the company recorded an increase of $40 million to APIC relating to net assets recorded as transferred as part of the 2019 Internal Reorganizations that were retained. 

Since 2018, Argentina has been considered a hyper-inflationary economy under U.S. GAAP and therefore the U.S. Dollar (“USD”) is the functional currency for our related subsidiaries. We remeasure the net monetary assets utilizing the official Argentine Peso (“Peso”) to USD exchange rate. The devaluation of the Peso relative to the USD over the last several years has resulted in the recognition of exchange losses (refer to Note 6 of these financial statements and Note 9 of the 2020 financial statements included in the Company's Annual Report on Form 10-K). As of March 31, 2021, a further 10% deterioration in the official Peso to USD exchange rate would reduce the USD value of our net monetary assets and negatively impact pre-tax earnings by approximately $20 million.

NOTE 2 - RECENT ACCOUNTING GUIDANCE

Recently Adopted Accounting Guidance
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which was part of the FASB’s Simplification Initiative to identify, evaluate, and improve areas of U.S. GAAP for which cost and complexity can be reduced, while maintaining or improving the usefulness of the information provided to users of financial statements. This ASU amends ASC 740, Income Taxes, by removing certain exceptions to the general principles, and clarifying and amending current guidance. The new standard is effective for fiscal years, and periods within those fiscal years, beginning after December 15, 2020. The company adopted this guidance on January 1, 2021 and it did not have a material impact on the company’s financial position, results of operation or cash flows.

NOTE 3 - DIVESTITURES AND OTHER TRANSACTIONS

Separation Agreements
In connection with the Distributions, DuPont, Corteva, and Dow (together, the “Parties” and each a “Party”) have entered into certain agreements to effect the Separation, provide for the allocation of DowDuPont’s assets, employees, liabilities and obligations (including its investments, property and employee benefits and tax-related assets and liabilities) among the Parties, and provide a framework for Corteva's relationship with Dow and DuPont following the separations and Distributions (collectively, the "Separation Agreements"). For additional information see Note 13 - Commitments and Contingent Liabilities.

DuPont
Pursuant to the Separation Agreements, DuPont and Corteva indemnifies the other against certain litigation, environmental, tax, workers' compensation and other liabilities that arose prior to the Corteva Distribution. The term of this indemnification is generally indefinite and includes defense costs and expenses, as well as monetary and non-monetary settlements and judgments. In connection with the recognition of liabilities related to these matters, the company records an indemnification asset when recovery is deemed probable. At March 31, 2021, the indemnification assets are $28 million within accounts and notes receivable - net and $51 million within other assets in the interim Condensed Consolidated Balance Sheet. At March 31, 2021, the indemnification liabilities are $77 million within other noncurrent obligations in the interim Condensed Consolidated Balance Sheet.

Dow
Pursuant to the Separation Agreements, Dow and Corteva indemnifies the other against certain litigation, environmental, tax and other liabilities that arose prior to the Corteva Distribution. The term of this indemnification is generally indefinite and
9
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

includes defense costs and expenses, as well as monetary and non-monetary settlements and judgments. In connection with the recognition of liabilities related to these matters, the company records an indemnification asset when recovery is deemed probable. At March 31, 2021, the indemnification liabilities are $52 million within accrued and other current liabilities and $14 million within other noncurrent obligations in the interim Condensed Consolidated Balance Sheet.

Performance Chemicals
On July 1, 2015, Historical DuPont completed the separation of its Performance Chemicals segment through the spin-off of all of the issued and outstanding stock of The Chemours Company (the "Chemours Separation"). In connection with the Chemours Separation, Historical DuPont and The Chemours Company ("Chemours") entered into a Separation Agreement (as amended, the "Chemours Separation Agreement"), discussed below, a Tax Matters Agreement and certain ancillary agreements, including an employee matters agreement, agreements related to transition and site services, and intellectual property cross licensing arrangements. In addition, the companies entered into certain supply agreements.

Separation Agreement
The Chemours Separation Agreement sets forth, among other things, the agreements between the company and Chemours regarding the principal transactions necessary to effect the Chemours Separation and also sets forth ancillary agreements that govern certain aspects of the company’s relationship with Chemours after the separation. Among other matters, the Chemours Separation Agreement and the ancillary agreements provide for the allocation between Historical DuPont and Chemours of assets, employees, liabilities and obligations (including investments, property and employee benefits and tax-related assets and liabilities) attributable to periods prior to, at and after the completion of the Chemours Separation.

Pursuant to the Chemours Separation Agreement, Chemours indemnifies the company against certain litigation, environmental, workers' compensation and other liabilities that arose prior to the distribution. The term of this indemnification is generally indefinite and includes defense costs and expenses, as well as monetary and non-monetary settlements and judgments. In 2017, EID and Chemours amended the Chemours Separation Agreement ("2017 Amendment") to provide for a limited sharing of potential future perfluorooctanoic acid (“PFOA”) liabilities for a period of five years beginning July 6, 2017. In January 2021, Chemours, DuPont and Corteva entered into a binding memorandum of understanding ("MOU") amending the Chemours Separation Agreement, and thereby replacing the 2017 Amendment.

In connection with the recognition of liabilities related to these matters, the company records an indemnification asset when recovery is deemed probable. At March 31, 2021, the indemnification assets are $63 million within accounts and notes receivable - net and $259 million within other assets (along with the corresponding liabilities within accrued and other current liabilities and other noncurrent obligations in the interim Condensed Consolidated Balance Sheet.) Additionally, at March 31, 2021 indemnification liabilities related to the MOU, primarily associated with environmental remediation related to PFAS, were $10 million within accrued and other current liabilities and $44 million within other noncurrent obligations in the interim Condensed Consolidated Balance Sheet. During the three months ended March 31, 2021, the company recorded a charge of $3 million to (loss) income from discontinued operations after income taxes, related to the MOU.

See Note 13 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements, for further discussion of the amendment to the Chemours Separation Agreement, MOU, and environmental matters indemnified by Chemours.


NOTE 4 - REVENUE

Revenue Recognition
Products
Substantially all of Corteva's revenue is derived from product sales. Product sales consist of sales of Corteva's products to farmers, distributors, and manufacturers. Corteva considers purchase orders, which in some cases are governed by master supply agreements, to be a contract with a customer. Contracts with customers are considered to be short-term when the time between order confirmation and satisfaction of the performance obligations is equal to or less than one year. However, the company has some long-term contracts which can span multiple years.

Revenue from product sales is recognized when the customer obtains control of the company's product, which occurs at a point in time according to shipping terms. Payment terms are generally less than one year from invoicing. The company elected the practical expedient and does not adjust the promised amount of consideration for the effects of a significant financing component when the company expects it will be one year or less between when a customer obtains control of the company's product and when payment is due. The company has elected to recognize shipping and handling activities when control has transferred to the customer as an expense in cost of goods sold. Taxes collected from customers relating to product sales and
10
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

remitted to governmental authorities are excluded from revenues. In addition, the company elected the practical expedient to expense any costs to obtain contracts as incurred, as the amortization period for these costs would have been one year or less.

The transaction price includes estimates of variable consideration, such as rights of return, rebates, and discounts, that are reductions in revenue. All estimates are based on the company's historical experience, anticipated performance, and the company's best judgment at the time the estimate is made. Estimates of variable consideration included in the transaction price utilize either the expected value method or most likely amount depending on the nature of the variable consideration. These estimates are reassessed each reporting period and are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur upon resolution of uncertainty associated with the variable consideration. The majority of contracts have a single performance obligation satisfied at a point in time and the transaction price is stated in the contract, usually as quantity times price per unit. For contracts with multiple performance obligations, the company allocates the transaction price to each performance obligation based on the relative standalone selling price. The standalone selling price is the observable price which depicts the price as if sold to a similar customer in similar circumstances.

Licenses of Intellectual Property
Corteva enters into licensing arrangements with customers under which it licenses its intellectual property. Revenue from the majority of intellectual property licenses is derived from sales-based royalties. Revenue for licensing agreements that contain sales-based royalties is recognized at the later of (i) when the subsequent sale occurs or (ii) when the performance obligation to which some or all of the royalty has been allocated is satisfied.

Remaining Performance Obligations
Remaining performance obligations represent the transaction price allocated to unsatisfied or partially unsatisfied performance obligations. The company applies the practical expedient to disclose the transaction price allocated to the remaining performance obligations for only those contracts with an original duration of one year or more. The transaction price allocated to remaining performance obligations with an original duration of more than one year related to material rights granted to customers for contract renewal options were $113 million at March 31, 2021 ($115 million and $106 million at December 31, 2020 and March 31, 2020, respectively). The company expects revenue to be recognized for the remaining performance obligations over the next 1 year to 6 years.

Contract Balances
Contract liabilities primarily reflect deferred revenue from prepayments under contracts with customers where the company receives advance payments for products to be delivered in future periods. Corteva classifies deferred revenue as current or noncurrent based on the timing of when the company expects to recognize revenue. Contract assets primarily include amounts related to contractual rights to consideration for completed performance not yet invoiced. Accounts receivable are recorded when the right to consideration becomes unconditional.
Contract Balances March 31, 2021 December 31, 2020 March 31, 2020
(In millions)
Accounts and notes receivable - trade1
$ 5,764  $ 3,917  $ 5,779 
Contract assets - current2
$ 22  $ 22  $ 20 
Contract assets - noncurrent3
$ 53  $ 54  $ 49 
Deferred revenue - current $ 2,247  $ 2,662  $ 1,996 
Deferred revenue - noncurrent4
$ 111  $ 116  $ 104 
1.Included in accounts and notes receivable - net in the interim Condensed Consolidated Balance Sheets.
2.Included in other current assets in the interim Condensed Consolidated Balance Sheets.
3.Included in other assets in the interim Condensed Consolidated Balance Sheets.
4.Included in other noncurrent obligations in the interim Condensed Consolidated Balance Sheets.

Revenue recognized during the three months ended March 31, 2021 from amounts included in deferred revenue at the beginning of the period was $924 million ($822 million in the three months ended March 31, 2020).


11
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)


Disaggregation of Revenue
Corteva's operations are classified into two reportable segments: Seed and Crop Protection. The company disaggregates its revenue by major product line and geographic region, as the company believes it best depicts the nature, amount and timing of its revenue and cash flows. Net sales by major product line are included below:
Three Months Ended
March 31,
(In millions) 2021 2020
    Corn $ 1,888  $ 1,864 
    Soybean 177  181 
    Other oilseeds 296  248 
    Other 131  162 
Seed 2,492  2,455 
    Herbicides 986  823 
    Insecticides 385  378 
    Fungicides 261  229 
    Other 54  71 
Crop Protection 1,686  1,501 
Total $ 4,178  $ 3,956 
.

Sales are attributed to geographic regions based on customer location. Net sales by geographic region and segment are included below:
Seed Three Months Ended
March 31,
(In millions) 2021 2020
North America1
$ 1,210  $ 1,290 
EMEA2
947  881 
Latin America 274  216 
Asia Pacific 61  68 
Total $ 2,492  $ 2,455 
Crop Protection Three Months Ended
March 31,
(In millions) 2021 2020
North America1
$ 533  $ 475 
EMEA2
655  586 
Latin America 244  218 
Asia Pacific 254  222 
Total $ 1,686  $ 1,501 
1.Represents U.S. & Canada.
2.Europe, Middle East, and Africa ("EMEA").

12
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 5 - RESTRUCTURING AND ASSET RELATED CHARGES - NET

2021 Restructuring Actions
As discussed in the 2020 Annual Report, on February 1, 2021, Corteva approved restructuring actions designed to right-size and optimize its footprint and organizational structure according to the business needs in each region with the focus on driving continued cost improvement and productivity. As a result of these actions, the company expects to record total pre-tax restructuring charges of approximately $130 million to $170 million, comprised of approximately $40 million to $50 million of severance and related benefit costs, $40 million to $60 million of asset related charges, $10 million to $15 million of asset retirement obligations and $40 million to $45 million of costs related to contract terminations (contract terminations includes early lease terminations). Future cash payments related to this charge are anticipated to be approximately $80 million to $100 million, primarily related to the payment of severance and related benefits, asset retirement obligations, and costs related to contract terminations. The restructuring actions associated with this charge are expected to be substantially complete in 2021.

The charges related to the 2021 Restructuring Actions related to the segments, as well as corporate expenses, were as follows:
Three Months Ended March 31,
(In millions) 2021
Seed $ 14 
Crop Protection 28 
Corporate expenses 47 
Total $ 89 

A reconciliation of the December 31, 2020 to the March 31, 2021 liability balances related to the 2021 Restructuring Actions is summarized below:
(In millions) Severance and Related Benefit Costs
Asset Related1
Contract Termination2
Total
Balance at December 31, 2020 —  —  —  $ — 
Charges to income from continuing operations for the three months ended March 31, 2021 39  13  37  89 
Payments (1) —  (6) (7)
Asset write-offs —  (13) —  (13)
Balance at March 31, 2021 $ 38  $ —  $ 31  $ 69 
1.In addition, the Company has a liability recorded for asset retirement obligations of $6 million as of March 31, 2021.
2.The liability for contract terminations includes lease obligations. The cash impact of these obligations will be substantially complete by 2022.

Execute to Win Productivity Program
During the first quarter of 2020, Corteva approved restructuring actions designed to improve productivity through optimizing certain operational and organizational structures primarily related to the Execute to Win Productivity Program. Through the first quarter of 2021, the company recorded net pre-tax restructuring charges of $180 million inception-to-date under the Execute to Win Program, consisting of $117 million of asset related charges and $63 million of severance and related benefit costs. The company does not anticipate any additional material charges from the Execute to Win Program as actions associated with this charge were substantially complete by the end of 2020.

The Execute to Win Productivity Program charges related to the segments, as well as corporate expenses, were as follows:
Three Months Ended March 31,
(In millions) 2021 2020
Seed $ —  $ 3 
Crop Protection 4  18 
Corporate expenses —  42 
Total $ 4  $ 63 

13
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

The below is a summary of charges incurred related to the Execute to Win Productivity Program for the three months ended March 31, 2021 and 2020:
Three Months Ended March 31,
(In millions) 2021 2020
Severance and related benefit costs $ —  $ 42 
Asset related charges 4  21 
Total restructuring and asset related charges - net $ 4  $ 63 

A reconciliation of the December 31, 2020 to the March 31, 2021 liability balances related to the Execute to Win Productivity Program is summarized below:
(In millions) Severance and Related Benefit Costs Asset Related Total
Balance at December 31, 2020 $ 53  $ 3  $ 56 
Charges to income from continuing operations for the three months ended March 31, 2021 —  4  4 
Payments (11) (3) (14)
Asset write-offs —  (4) (4)
Balance at March 31, 2021 $ 42  $ —  $ 42 

In addition to the above, the company has a liability recorded for asset retirement obligations of $20 million as of March 31, 2021. The asset retirement obligations relate to the company’s required demolition and removal for buildings and equipment at third party leased sites and will be recognized as asset related charges over the remaining useful lives of the related assets.  The company’s leases require these assets be removed from leased land within 12-24 months of operations being ceased. The company ceased substantially all operations in 2020 and the assets are expected to be removed within the contractual timeframe.

Other Asset Related Charges
During the three months ended March 31, 2021 and 2020, the company recognized $7 million and $10 million, respectively, in restructuring and asset related charges, net in the interim Consolidated Statement of Operations, from non-cash accelerated prepaid royalty amortization expense related to Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits.

NOTE 6 - SUPPLEMENTARY INFORMATION
Other Income - Net Three Months Ended
March 31,
(In millions) 2021 2020
Interest income $ 21  $ 18 
Equity in earnings / (losses) of affiliates - net 3  (1)
Net loss on sales of businesses and other assets1
—  (46)
Net exchange losses2
(35) (61)
Non-operating pension and other post employment benefit credit3
325  91 
Miscellaneous income - net4
23  — 
Other income - net $ 337  $ 1 
 
1.The three months ended March 31, 2020 includes a loss of $(53) million relating to the sale of the La Porte site, for which the company signed an agreement in 2020, and closed during the first quarter of 2021.
2.Includes net pre-tax exchange losses of $(23) million and $(9) million associated with the devaluation of the Argentine peso for the three months ended March 31, 2021 and 2020, respectively.
3.Includes non-service related components of net periodic benefit credits (costs) (interest cost, expected return on plan assets, amortization of unrecognized gain (loss), amortization of prior service benefit and settlement loss).
4.Miscellaneous income - net, includes a gain from a remeasurement of an equity investment, losses on sale of available-for-sale securities, tax indemnification adjustments related to changes in indemnification balances as a result of the application of the terms of the Tax Matters Agreement between Corteva and Dow and/or DuPont, losses on sale of receivables, and other items.
14
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

The following table summarizes the impacts of the company's foreign currency hedging program on the company's results of operations. The company routinely uses foreign currency exchange contracts to offset its net exposures, by currency, related to the foreign currency-denominated monetary assets and liabilities. The objective of this program is to maintain an approximately balanced position in foreign currencies in order to minimize, on an after-tax basis, the effects of exchange rate changes on net monetary asset positions. The hedging program gains (losses) are largely taxable (tax deductible) in the U.S., whereas the offsetting exchange gains (losses) on the remeasurement of the net monetary asset positions are often not taxable (tax deductible) in their local jurisdictions. The net pre-tax exchange gains (losses) are recorded in other income - net and the related tax impact is recorded in provision for (benefit from) income taxes on continuing operations in the interim Consolidated Statement of Operations.
(In millions) Three Months Ended
March 31,
2021 2020
Subsidiary Monetary Position (Losses) Gains
Pre-tax exchange losses $ (51) $ (226)
Local tax (expenses) / benefits (1) 23 
Net after-tax impact from subsidiary exchange losses $ (52) $ (203)
Hedging Program Gains
Pre-tax exchange gains $ 16  $ 165 
Tax expenses (4) (40)
Net after-tax impact from hedging program exchange gains $ 12  $ 125 
Total Exchange Losses
Pre-tax exchange losses $ (35) $ (61)
Tax expenses (5) (17)
Net after-tax exchange losses $ (40) $ (78)
Cash, cash equivalents and restricted cash
The following table provides a reconciliation of cash and cash equivalents and restricted cash (included in other current assets) presented in the interim Condensed Consolidated Balance Sheets to the total cash, cash equivalents and restricted cash presented in the interim Consolidated Statements of Cash Flows.
(In millions) March 31, 2021 December 31, 2020 March 31, 2020
Cash and cash equivalents $ 2,404  $ 3,526  $ 1,963 
Restricted cash 326  347  377 
Total cash, cash equivalents and restricted cash $ 2,730  $ 3,873  $ 2,340 

EID entered into a trust agreement in 2013 (as amended and restated in 2017), establishing and requiring EID to fund a trust (the "Trust") for cash obligations under certain non-qualified benefit and deferred compensation plans upon a change in control event as defined in the Trust agreement. Under the Trust agreement, the consummation of the Merger was a change in control event. Restricted cash at March 31, 2021, December 31, 2020, and March 31, 2020 is related to the Trust.

15
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 7 - INCOME TAXES

For periods between the Merger Effectiveness Time and the Corteva Distribution, Corteva and its subsidiaries were included in DowDuPont's consolidated federal income tax group and consolidated tax return.  Generally, the consolidated tax liability of the DowDuPont U.S. tax group for each year was apportioned among the members of the consolidated group based on each member’s separate taxable income.  Corteva, DuPont and Dow intend that to the extent Federal and/or State corporate income tax liabilities are reduced through the utilization of tax attributes of the other, settlement of any receivable and payable generated from the use of the other party’s sub-group attributes will be in accordance with a tax matters agreement. See Note 3 - Divestitures and Other Transactions, for further information related to indemnifications between Corteva, Dow and DuPont.

Each year the company files hundreds of tax returns in the various national, state and local income taxing jurisdictions in which it operates. These tax returns are subject to examination and possible challenge by the tax authorities. Positions challenged by the tax authorities may be settled or appealed by the company. As a result, there is an uncertainty in income taxes recognized in the company's financial statements in accordance with accounting for income taxes and accounting for uncertainty in income taxes. The ultimate resolution of such uncertainties is not expected to have a material impact on the company's results of operations.

The company routinely uses foreign currency exchange contracts to offset its net exposures, by currency, related to the foreign currency-denominated monetary assets and liabilities. The objective of the program, which resides in the U.S., is to maintain an approximately balanced position in foreign currencies in order to minimize, on an after-tax basis, the effects of exchange rate changes on net monetary asset positions, which can drive material impacts on the company's effective tax rate. For further discussion of pre-tax and after-tax impacts of the company's foreign currency hedging program and net monetary asset programs, refer to Note 6 - Supplementary Information.

16
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 8 - EARNINGS PER SHARE OF COMMON STOCK

The following tables provide earnings per share calculations for the periods indicated below:
Net Income for Earnings Per Share Calculations - Basic and Diluted Three Months Ended
March 31,
(In millions) 2021 2020
Income from continuing operations after income taxes $ 613  $ 281 
Net income attributable to continuing operations noncontrolling interests 3  10 
Income from continuing operations available to Corteva common stockholders 610  271 
(Loss) income from discontinued operations available to Corteva common stockholders (10) 1 
Net income available to common stockholders $ 600  $ 272 
Earnings Per Share Calculations - Basic Three Months Ended
March 31,
(Dollars per share) 2021 2020
Earnings per share of common stock from continuing operations
$ 0.82  $ 0.36 
Loss per share of common stock from discontinued operations (0.01) — 
Earnings per share of common stock $ 0.81  $ 0.36 
Earnings Per Share Calculations - Diluted Three Months Ended
March 31,
(Dollars per share) 2021 2020
Earnings per share of common stock from continuing operations $ 0.81  $ 0.36 
Loss per share of common stock from discontinued operations (0.01) — 
Earnings per share of common stock $ 0.80  $ 0.36 
Share Count Information Three Months Ended
March 31,
(Shares in millions) 2021 2020
Weighted-average common shares - basic 743.4  749.9 
Plus dilutive effect of equity compensation plans1
6.2  2.6 
Weighted-average common shares - diluted 749.6  752.5 
Potential shares of common stock excluded from EPS calculations2
2.9  9.1 
1.Diluted earnings per share considers the impact of potentially dilutive securities except in periods in which there is a loss because the inclusion of the potential common shares would have an anti-dilutive effect.
2.These outstanding potential shares of common stock relating to stock options, restricted stock units and performance-based restricted stock units were excluded from the calculation of diluted earnings per share because the effect of including them would have been anti-dilutive.
17
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 9 - ACCOUNTS AND NOTES RECEIVABLE - NET
(In millions) March 31, 2021 December 31, 2020 March 31, 2020
Accounts receivable – trade1
$ 5,231  $ 3,754  $ 5,367 
Notes receivable – trade1,2
533  163  412 
Other3
1,028  1,009  996 
Total accounts and notes receivable - net $ 6,792  $ 4,926  $ 6,775 
1.Accounts receivable – trade and notes receivable - trade are net of allowances of $203 million at March 31, 2021, $208 million at December 31, 2020, and $203 million at March 31, 2020. Allowances are equal to the estimated uncollectible amounts and are based on the expected credit losses and were developed using a loss-rate method.
2.Notes receivable – trade primarily consists of receivables for deferred payment loan programs for the sale of seed products to customers. These loans have terms of one year or less and are primarily concentrated in North America. The company maintains a rigid pre-approval process for extending credit to customers in order to manage overall risk and exposure associated with credit losses. As of March 31, 2021, December 31, 2020, and March 31, 2020 there were no significant impairments related to current loan agreements.
3.Other includes receivables in relation to indemnification assets, value added tax, general sales tax and other taxes. No individual group represents more than 10 percent of total receivables. In addition, Other includes amounts due from nonconsolidated affiliates of $115 million, $106 million, and $140 million as of March 31, 2021, December 31, 2020, and March 31, 2020, respectively.

Accounts and notes receivable are carried at the expected amount to be collected, which approximates fair value. The company establishes the allowance for doubtful receivables using a loss-rate method where the loss rate is developed using past events, historical experience, current conditions and forecasts that affect the collectability of the financial assets.

The following table summarizes changes in the allowance for doubtful receivables for the three months ended March 31, 2021 and 2020:
(In millions)
2020
Balance at December 31, 2019 $ 174 
Net provision for credit losses 60 
Write-offs charged against allowance (1)
Recoveries collected (30)
Balance at March 31, 2020
$ 203 
2021
Balance at December 31, 2020 $ 208 
Net benefit for credit losses (5)
Balance at March 31, 2021
$ 203 

The company enters into various factoring agreements with third-party financial institutions to sell its trade receivables under both recourse and non-recourse agreements in exchange for cash proceeds. These financing arrangements result in a transfer of the company's receivables and risks to the third-party. As these transfers qualify as true sales under the applicable accounting guidance, the receivables are derecognized from the interim Condensed Consolidated Balance Sheets upon transfer, and the company receives a payment for the receivables from the third-party within a mutually agreed upon time period. For arrangements involving an element of recourse, which is typically provided through a guarantee of accounts in the event of customer default, the guarantee obligation is measured using market data from similar transactions and reported as a current liability in the interim Condensed Consolidated Balance Sheets.

Trade receivables sold under these agreements were $11 million and $15 million for the three months ended March 31, 2021 and March 31, 2020, respectively. The trade receivables sold that remained outstanding under these agreements which include an element of recourse as of March 31, 2021, December 31, 2020, and March 31, 2020 were $128 million, $157 million, and $43 million, respectively. The net proceeds received are included in cash provided by operating activities in the interim Consolidated Statements of Cash Flows. The difference between the carrying amount of the trade receivables sold and the sum of the cash received is recorded as a loss on sale of receivables in other income - net in the Consolidated Statements of Operations. Loss on sale of receivables for the three months ended March 31, 2021 and 2020 were not material. The guarantee obligations recorded as of March 31, 2021, December 31, 2020, and March 31, 2020 in the interim Condensed Consolidated Balance Sheets were not material. See Note 13 - Commitments and Contingent Liabilities for additional information on the company’s guarantees.
18
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 10 - INVENTORIES
(In millions) March 31, 2021 December 31, 2020 March 31, 2020
Finished products $ 2,508  $ 2,584  $ 2,721 
Semi-finished products 1,386  1,813  1,260 
Raw materials and supplies 427  485  420 
Total inventories $ 4,321  $ 4,882  $ 4,401 



NOTE 11 - OTHER INTANGIBLE ASSETS

The gross carrying amounts and accumulated amortization of other intangible assets by major class are as follows: 
(In millions) March 31, 2021 December 31, 2020 March 31, 2020
  Gross Accumulated
Amortization 		Net Gross Accumulated
Amortization 		Net Gross Accumulated
Amortization 		Net
Intangible assets subject to amortization (Definite-lived):
           
Germplasm $ 6,265  $ (380) $ 5,885  $ 6,265  $ (317) $ 5,948  $ 6,265  $ (126) $ 6,139 
Customer-related
1,956  (404) 1,552  1,984  (380) 1,604  1,956  (293) 1,663 
Developed technology
1,485  (565) 920  1,451  (525) 926  1,463  (409) 1,054 
Trademarks/trade names1
2,013  (112) 1,901  2,019  (99) 1,920  166  (88) 78 
Favorable supply contracts
475  (326) 149  475  (302) 173  475  (231) 244 
Other2
405  (238) 167  405  (239) 166  400  (218) 182 
Total other intangible assets with finite lives
12,599  (2,025) 10,574  12,599  (1,862) 10,737  10,725  (1,365) 9,360 
Intangible assets not subject to amortization (Indefinite-lived):
           
IPR&D 10  —  10  10  —  10  10  —  10 
Trade name1
1,871  —  1,871 
Total other intangible assets 10  —  10  10  —  10  1,881  —  1,881 
Total $ 12,609  $ (2,025) $ 10,584  $ 12,609  $ (1,862) $ 10,747  $ 12,606  $ (1,365) $ 11,241 
1.Beginning on October 1, 2020, the company changed its indefinite life assertion of its trade name asset to definite lived with a useful life of 25 years. This change is the result of the launch of BrevantTM seed in the retail channel in the U.S. Prior to changing the useful life of the trade name asset, the company tested the asset for the impairment under ASC 350- Intangibles, Goodwill and Other, concluding the asset was not impaired.
2.Primarily consists of sales and farmer networks, marketing and manufacturing alliances and noncompetition agreements.

The aggregate pre-tax amortization expense from continuing operations for definite-lived intangible assets was $183 million and $163 million for the three months ended March 31, 2021 and 2020, respectively. The current estimated aggregate pre-tax amortization expense from continuing operations for the remainder of 2021 and each of the next five years is approximately $537 million, $700 million, $620 million, $606 million, $569 million and $555 million, respectively.


19
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)


NOTE 12 - SHORT-TERM BORROWINGS, LONG-TERM DEBT AND AVAILABLE CREDIT FACILITIES

The following tables summarize Corteva's short-term borrowings and finance lease obligations:
Short-term borrowings and finance lease obligations
(In millions) March 31, 2021 December 31, 2020 March 31, 2020
Commercial paper $ 1,218  $ —  $ 1,918 
Repurchase facility 30  —  30 
Other loans - various currencies —  1  45 
Long-term debt payable within one year 1  1  1 
Finance lease obligations payable within one year 1  1  2 
Total short-term borrowings and finance lease obligations $ 1,250  $ 3  $ 1,996 

The estimated fair value of the company's short-term borrowings, including interest rate financial instruments, was determined using Level 2 inputs within the fair value hierarchy. Based on quoted market prices for the same or similar issues, or on current rates offered to the company for debt of the same remaining maturities, the fair value of the company's short-term borrowings and finance lease obligations was approximately carrying value.

The fair value of the company’s long-term borrowings, including debt due within one year, was $1,121 million, $1,168 million, and $612 million as of March 31, 2021, December 31, 2020, and March 31, 2020, respectively, and was determined using quoted market prices for the same or similar issues, or current rates offered to the company for debt of the same remaining maturities (Level 2 inputs).

Repurchase Facility
In February 2021, the company entered into a new committed receivable repurchase facility of up to $1 billion (the "2021 Repurchase Facility") which expires in December 2021. Under the 2021 Repurchase Facility, Corteva may sell a portfolio of available and eligible outstanding customer notes receivables to participating institutions and simultaneously agree to repurchase at a future date. The 2021 Repurchase Facility is considered a secured borrowing with the customer notes receivables inclusive of those that are sold and repurchased, equal to 105 percent of the outstanding amounts borrowed utilized as collateral. Borrowings under the 2021 Repurchase Facility have an interest rate of LIBOR+0.85 percent.

As of March 31, 2021, $32 million of notes receivable, recorded in accounts and notes receivable - net, were pledged as collateral against outstanding borrowings under the 2021 Repurchase Facility of $30 million, recorded in short-term borrowings and finance lease obligations on the interim Condensed Consolidated Balance Sheet.

Revolving Credit Facilities
In November 2018, EID entered into a $3.0 billion 5-year revolving credit facility and a $3.0 billion 3-year revolving credit facility (the “Revolving Credit Facilities”). The Revolving Credit Facilities became effective May 2019. Corteva, Inc. became a party at the time of the Corteva Distribution. The Revolving Credit Facilities may serve as a substitute to the company's commercial paper program, and can be used, from time to time, for general corporate purposes including, but not limited to, the funding of seasonal working capital needs. The Revolving Credit Facilities contain customary representations and warranties, affirmative and negative covenants and events of default that are typical for companies with similar credit ratings. Additionally, the Revolving Credit Facilities contain a financial covenant requiring that the ratio of total indebtedness to total capitalization for Corteva and its consolidated subsidiaries not exceed 0.60.

In March 2020, the company drew down $500 million under the $3.0 billion 3-year revolving credit facility as a result of the volatility and increased borrowing costs of commercial paper resulting from the unstable market conditions caused by the COVID-19 pandemic and repaid that borrowing in full in June 2020. There were no additional borrowings and the unused commitments under the 3-year revolving credit facility were $3.0 billion as of March 31, 2021.


20
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 13 - COMMITMENTS AND CONTINGENT LIABILITIES

Guarantees
Indemnifications
In connection with acquisitions and divestitures as of March 31, 2021, the company has indemnified respective parties against certain liabilities that may arise in connection with these transactions and business activities prior to the completion of the transactions. The term of these indemnifications, which typically pertain to environmental, tax and product liabilities, is generally indefinite. In addition, the company indemnifies its duly elected or appointed directors and officers to the fullest extent permitted by Delaware law, against liabilities incurred as a result of their activities for the company, such as adverse judgments relating to litigation matters. If the indemnified party were to incur a liability or have a liability increase as a result of a successful claim, pursuant to the terms of the indemnification, the company would be required to reimburse the indemnified party. The maximum amount of potential future payments is generally unlimited. See pages 9 and 22 for additional information relating to the indemnification obligations under the Chemours Separation Agreement and the Corteva Separation Agreement.

Obligations for Customers and Other Third Parties
The company has directly guaranteed various debt obligations under agreements with third parties related to customers and other third parties. At March 31, 2021, December 31, 2020 and March 31, 2020, the company had directly guaranteed $108 million, $94 million, and $90 million, respectively, of such obligations. These amounts represent the maximum potential amount of future (undiscounted) payments that the company could be required to make under the guarantees in the event of default by the guaranteed party. All of the maximum future payments at March 31, 2021 had terms less than one year. The maximum future payments include $23 million at March 31, 2021 and $17 million at December 31, 2020 and March 31, 2020, respectively, of guarantees related to the various factoring agreements that the company enters into with third-party financial institutions to sell its trade receivables. See Note 9 - Accounts and Notes Receivable, Net, for additional information.

The maximum future payments also include agreements with lenders to establish programs that provide financing for select customers. The terms of the guarantees are equivalent to the terms of the customer loans that are primarily made to finance customer invoices. The total amounts owed from customers to the lenders relating to these agreements was $178 million, $16 million and $125 million at March 31, 2021, December 31, 2020 and March 31, 2020, respectively.

The company assesses the payment/performance risk by assigning default rates based on the duration of the guarantees. These default rates are assigned based on the external credit rating of the counterparty or through internal credit analysis and historical default history for counterparties that do not have published credit ratings. For counterparties without an external rating or available credit history, a cumulative average default rate is used.

Litigation
The company is subject to various legal proceedings, including, but not limited to, product liability, intellectual property, antitrust, commercial, property damage, personal injury, environmental and regulatory matters arising out of the normal course of its current businesses or legacy EID businesses unrelated to Corteva’s current businesses but allocated to Corteva as part of the separation of Corteva from DuPont. It is not possible to predict the outcome of these various proceedings, as considerable uncertainty exists.  However, the ultimate liabilities could be material to results of operations and the cash flows in the period recognized.

Indemnifications under Separation Agreements
The company has entered into various agreements where the company is indemnified for certain liabilities. In connection with the recognition of liabilities related to these matters, the company records an indemnification asset when recovery is deemed probable. See Note 3 - Divestitures and Other Transactions, to the interim Consolidated Financial Statements for additional information related to indemnifications.

Chemours/Performance Chemicals
Refer to Note 3 - Divestitures and Other Transactions, to the interim Consolidated Financial Statements for additional discussion of the Chemours Separation Agreement.

In 2017, EID and Chemours amended the Chemours Separation Agreement to provide for a limited sharing of potential future liabilities related to alleged historical releases of perfluorooctanoic acids and its ammonium salts (“PFOA”) for a five-year period that began on July 6, 2017. In addition, in 2017, Chemours and EID each paid $335 million to settle multi-district litigation in the U.S. District Court for the Southern District of Ohio (“Ohio MDL”), thereby resolving claims of about 3,550 plaintiffs alleging injury from exposure to PFOA in drinking water as a result of the historical manufacture or use of PFOA at the Washington Works plant outside Parkersburg, West Virginia. This plant was previously owned and/or operated by the performance chemicals segment of EID and is now owned and/or operated by Chemours. The 2017 settlement did not resolve
21
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

claims of certain class members who did not have claims in the Ohio MDL or whose claims are based on diseases first diagnosed after February 11, 2017. About 96 claims alleging personal injury were filed in the Ohio MDL since the 2017 settlement and a number of additional pre-suit claims for personal injury were asserted.

On May 13, 2019, Chemours filed suit in the Delaware Court of Chancery against DuPont, EID, and Corteva, seeking, among other things, to limit its responsibility for the litigation and environmental liabilities allocated to and assumed by Chemours under the Chemours Separation Agreement (the “Delaware Litigation”). On March 30, 2020, the Court of Chancery granted a motion to dismiss. On December 15, 2020, the Delaware Supreme Court affirmed the judgment of the Court of Chancery. Meanwhile, a confidential arbitration process regarding the same and other claims had proceeded (the “Pending Arbitration”).

For additional information regarding environmental indemnification, see discussion on page 25.

On January 22, 2021, Chemours, DuPont, Corteva and EID entered into a binding memorandum of understanding containing a settlement to resolve legal disputes originating from the Delaware Litigation and Pending Arbitration, and to establish a cost sharing arrangement and escrow account to be used to support and manage potential future legacy per- and polyfluoroalkyl substances (“PFAS”) liabilities arising out of pre-July 1, 2015 conduct (the “MOU”). The MOU replaces the 2017 amendment to the Chemours Separation Agreement. According to the terms of the cost sharing arrangement within the MOU, Corteva and DuPont together, on one hand, and Chemours, on the other hand, agreed to a 50-50 split of certain qualified expenses related to PFAS liabilities incurred over a term not to exceed twenty years or $4 billion of qualified spend and escrow account contributions (see below for discussion of escrow account) in the aggregate. DuPont’s and Corteva’s 50% share under the MOU will be limited to $2 billion, including qualified expenses and escrow contributions. These expenses and escrow account contributions will be subject to the existing Letter Agreement, under which DuPont and Corteva will each bear 50% of the first $300 million (up to $150 million each), and thereafter DuPont bears 71% and Corteva bears the remaining 29%.

In order to support and manage any potential future PFAS liabilities, the parties have also agreed to establish an escrow account. The MOU provides that (1) no later than each of September 30, 2021 and September 30, 2022, Chemours shall deposit $100 million into an escrow account and DuPont and Corteva shall together deposit $100 million in the aggregate into an escrow account and (2) no later than September 30 of each subsequent year through and including 2028, Chemours shall deposit $50 million into an escrow account and DuPont and Corteva shall together deposit $50 million in the aggregate into an escrow account. Subject to the terms and conditions set forth in the MOU, each party may be permitted to defer funding in any year (excluding 2021). Over this period, Chemours will deposit a total of $500 million in the account and DuPont and Corteva will deposit an additional $500 million pursuant to the terms of the Letter Agreement. Additionally, if on December 31, 2028, the balance of the escrow account (including interest) is less than $700 million, Chemours will make 50% of the deposits and DuPont and Corteva together will make 50% of the deposits necessary to restore the balance of the escrow account to $700 million. Such payments will be made in a series of consecutive annual equal installments commencing on September 30, 2029 pursuant to the escrow account replenishment terms as set forth in the MOU.

After the term of this arrangement, Chemours’ indemnification obligations under the original 2015 Chemours Separation Agreement, would continue unchanged, subject in each case to certain exceptions set out in the MOU. Under the MOU, Chemours waived specified claims regarding the construct of its 2015 spin-off transaction, and the parties will dismiss the pending arbitration regarding those claims (as discussed below). Additionally, the parties have agreed to resolve the Ohio MDL PFOA personal injury litigation (as discussed below). The parties are expected to cooperate in good faith to enter into additional agreements reflecting the terms set forth in the MOU.

Corteva Separation Agreement
On April 1, 2019, in connection with the Dow Distribution, Corteva, DuPont and Dow entered into the Corteva Separation Agreement, the Tax Matters Agreement, the Employee Matters Agreement, and certain other agreements (collectively, the “Corteva Separation Agreements”). The Corteva Separation Agreements allocate among Corteva, DuPont and Dow certain liabilities and obligations among the parties and provides for indemnification obligation among the parties. Under the Corteva Separation Agreements, DuPont will indemnify Corteva against certain litigation, environmental, workers' compensation and other liabilities that arose prior to the Corteva Distribution and (ii) Dow indemnifies Corteva against certain litigation and other liabilities that relate to the Historical Dow business, but were transferred over as part of the common control combination with DAS, and Corteva indemnifies DuPont and Dow for certain liabilities. The term of this indemnification is generally indefinite with exceptions, and includes defense costs and expenses, as well as monetary and non-monetary settlements and judgments. See Note 3 - Divestitures and Other Transactions, to the interim Consolidated Financial Statements for additional information relating to the Separation.


22
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

DuPont
Under the Corteva Separation Agreement, certain legacy EID liabilities from discontinued and/or divested operations and businesses of EID (including Performance Chemicals) (a “stray liability”) were allocated to Corteva or DuPont. For those stray liabilities allocated to Corteva (which may include a specified amount of liability associated with that liability), Corteva is responsible for liabilities in an amount up to that specified amount plus an additional $200 million and, for those stray liabilities allocated to DuPont (which may include a specified amount of liability associated with that liability), DuPont is responsible for liabilities up to a specified amount plus an additional $200 million. Once each company has met the $200 million threshold, Corteva and DuPont will share future liabilities proportionally on the basis of 29% and 71%, respectively; provided, however, that for PFAS, DuPont will manage such liabilities with Corteva and DuPont sharing the costs on a 50% - 50% basis starting from $1 and up to $300 million (with such amount, up to $150 million, to be credited to each company’s $200 million threshold) and once the $300 million threshold is met, then the companies will share proportionally on the basis of 29% and 71% respectively, subject to a $1 million de minimis requirement.

Litigation related to legacy EID businesses unrelated to Corteva’s current businesses

PFAS, PFOA, PFOS and Other Related Liabilities
For purposes of this report, the term PFOA means collectively perfluorooctanoic acid and its salts, including the ammonium salt and does not distinguish between the two forms, and PFAS, which means per- and polyfluoroalkyl substances, including PFOA, PFOS (perfluorooctanesulfonic acid), GenX and other perfluorinated chemicals and compounds ("PFCs").

EID is a party to various legal proceedings relating to the use of PFOA by its former Performance Chemicals segment for which potential liabilities would be subject to the cost sharing arrangement under the MOU as long as it remains effective. Management believes that it is reasonably possible that EID could incur liabilities related to PFOA in excess of amounts accrued. However, any such losses are not estimable at this time due to various reasons, including, among others, that the underlying matters are in their early stages and have significant factual issues to be resolved. The company has recorded a liability of $21 million and an indemnification asset of $16 million at March 31, 2021, related to testing drinking water in and around certain former EID sites and offering treatment or an alternative supply of drinking water if tests indicate the presence of PFOA in drinking water at or greater than the national health advisory level established from time to time by the EPA.

Leach Settlement and Ohio MDL Settlement
EID has residual liabilities under its 2004 settlement of a West Virginia state court class action, Leach v. EID, which alleged that PFOA from EID’s former Washington Works facility had contaminated area drinking water supplies and affected the health of area residents. The settlement class has about 80,000 members. In addition to relief that was provided to class members years ago, the settlement requires EID to continue providing PFOA water treatment to six area water districts and private well users and to fund, through an escrow account, up to $235 million for a medical monitoring program for eligible class members. As of March 31, 2021, approximately $2 million had been disbursed from the account since its establishment in 2012 and the remaining balance is approximately $1 million.

The Leach settlement permits class members to pursue personal injury claims for six health conditions (and no others) that an expert panel appointed under the settlement reported in 2012 had a “probable link” (as defined in the settlement) with PFOA: pregnancy-induced hypertension, including preeclampsia; kidney cancer; testicular cancer; thyroid disease; ulcerative colitis; and diagnosed high cholesterol. After the panel reported its findings, approximately 3,550 personal injury lawsuits were filed in federal and state courts in Ohio and West Virginia and consolidated in multi-district litigation in the U.S. District Court for the Southern District of Ohio (“Ohio MDL”). The Ohio MDL was settled in early 2017 for $670.7 million in cash, with Chemours and EID (without indemnification from Chemours) each paying half.

Post-MDL Settlement PFOA Personal Injury Claims
The 2017 Ohio MDL settlement did not resolve claims of plaintiffs who did not have claims in the Ohio MDL or whose claims are based on diseases first diagnosed after February 11, 2017. The first trial for these claims, a kidney cancer case, resulted in a hung jury, while the second, Travis and Julie Abbot v. E.I du Pont de Nemours and Company (the “Abbot Case”), a testicular cancer case, resulted in a jury verdict of $40 million in compensatory damages and $10 million for loss of consortium. Following entry of the judgment by the court, EID filed post-trial motions to reduce the verdict, and to appeal the verdict on the basis of procedural and substantive legal errors made by the trial court. The trial court recently granted EID’s motion to reduce the loss of consortium award to conform with state tort reform laws limiting these damages to $250,000. The company is continuing its other appeals to reduce the jury verdict or eliminate its liability, in whole or part.

In January 2021, Chemours, DuPont and Corteva agreed to settle the remaining approximately 95 matters, as well as unfiled matters, remaining in the Ohio MDL, with the exception of the Abbot case, for $83 million, with Chemours contributing $29 million to the settlement, and DuPont and Corteva contributing $27 million each. The company recorded a liability for its share
23
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

of the settlement, with a charge to (loss) income from discontinued operations after income taxes, during the year ended December 31, 2020, and paid $16 million during the three months ended March 31, 2021. Following this settlement, the parties have agreed to petition the court for the dissolution of the MDL.

Other PFOA Matters
EID is a party to other PFOA lawsuits that do not involve claims for personal injury. Defense costs and any future liabilities that may arise out of these lawsuits are subject to the MOU and the cost sharing arrangement disclosed above. Under the MOU, fraudulent conveyance claims associated with these matters are not qualified expenses, unless Corteva, Inc. and EID would prevail on the merits of these claims.

New York. EID is a defendant in about 50 lawsuits, including a putative class action, brought by persons who live in and around Hoosick Falls, New York. These lawsuits assert claims for medical monitoring and property damage based on alleged PFOA releases from manufacturing facilities owned and operated by co-defendants in Hoosick Falls and allege that EID and 3M supplied some of the materials used at these facilities. EID is also one of more than ten defendants in a lawsuit brought by the Town of East Hampton, New York alleging PFOA and PFOS contamination of the town’s well water. Additionally, EID, along with 3M, Chemours and Dyneon, have been named defendants in complaints filed by eight water districts in Nassau County, New York alleging that the drinking water they provide to customers is contaminated with PFAS and seeking reimbursement for clean-up costs. The water district complaints also include allegations of fraudulent transfer.

New Jersey. At March 31, 2021, two lawsuits were pending, one brought by a local water utility and the second a putative class action, against EID alleging that PFOA from EID’s former Chambers Works facility contaminated drinking water sources. The putative class action was voluntarily dismissed without prejudice by the plaintiff.

In late March of 2019, the New Jersey State Attorney General filed four lawsuits against EID, Chemours, 3M and others alleging that operations at and discharges from former EID sites in New Jersey (Chambers Works, Pompton Lakes, Parlin and Repauno) damaged the State’s natural resources. Two of these lawsuits (those involving the Chambers Works and Parlin sites) allege contamination from PFAS. The Ridgewood Water District in New Jersey filed suit in the first quarter 2019 against EID, 3M, Chemours, and Dyneon alleging losses related to the investigation, remediation and monitoring of polyfluorinated surfactants, including PFOA, in water supplies. DuPont and Corteva were subsequently added as defendants to these lawsuits.

Alabama / Others. EID is one of more than thirty defendants in a lawsuit by the Alabama water utility alleging contamination from PFCs, including PFOA, used by co-defendant carpet manufacturers to make their products more stain and grease resistant. In addition, the states of Alaska, Michigan, Mississippi, New Hampshire, South Dakota, and Vermont recently filed lawsuits against EID, Chemours, 3M and others, claiming, among other things, PFC (including PFOA) contamination of groundwater and drinking water. The complaints seek reimbursement for past and future costs to investigate and remediate the alleged contamination and compensation for the loss of value and use of the state’s natural resources. Motions to dismiss the Michigan, Vermont and New Hampshire cases have been denied. Additionally, the State of Delaware has indicated it may file a similar natural resource claim related to alleged PFAS contamination and other contaminants.

Ohio. EID is a defendant in three lawsuits: an action by the State of Ohio based on alleged damage to natural resources, a putative nationwide class action brought on behalf of anyone who has detectable levels of PFAS in their blood serum, and an action by the City of Dayton claiming losses related to the investigation, remediation and monitoring of PFAS in water supplies.

Aqueous Firefighting Foams. Approximately 985 cases have been filed against 3M and other defendants, including EID and Chemours, and more recently also including Corteva and DuPont, alleging PFOS or PFOA contamination of soil and groundwater from the use of aqueous firefighting foams. Most of those cases claim some form of property damage and seek to recover the costs of responding to this contamination and damages for the loss of use and enjoyment of property and diminution in value. Most of these cases have been transferred to a multidistrict litigation proceeding in federal district court in South Carolina. Approximately 910 of these cases were filed on behalf of firefighters who allege personal injuries (primarily kidney and testicular cancer) as a result of aqueous firefighting foams. Most of these recent cases assert claims that the EID and Chemours separation constituted a fraudulent conveyance. A schedule of initial trials is expected to be established in the second quarter of 2021.

EID did not make firefighting foams, PFOS, or PFOS products. While EID made surfactants and intermediaries that some manufacturers used in making foams, which may have contained PFOA as an unintended byproduct or an impurity, EID’s
24
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

products were not formulated with PFOA, nor was PFOA an ingredient of these products. EID has never made or sold PFOA as a commercial product.

Fayetteville Works Facility, North Carolina
Prior to the separation of Chemours, EID introduced GenX as a polymerization processing aid and a replacement for PFOA at the Fayetteville Works facility in Bladen County, North Carolina. The facility is now owned and operated by Chemours, which continues to manufacture and use GenX.

At March 31, 2021, several actions are pending in federal court against Chemours and EID relating to PFC discharges from the Fayetteville Works facility. One of these is a consolidated putative class action that asserts claims for medical monitoring and property damage on behalf of putative classes of property owners and residents in areas near or who draw drinking water from the Cape Fear River. Another action is a consolidated action brought by various North Carolina water authorities, including the Cape Fear Public Utility Authority and Brunswick County, that seek actual and punitive damages as well as injunctive relief. In another action over approximately 100 property owners near the Fayetteville Works facility filed a complaint against Chemours and EID in May 2020. The plaintiffs seek compensatory and punitive damages for their claims of private nuisance, trespass, and negligence allegedly caused by release of PFAS.

In addition to the federal court actions, there is an action on behalf of about 100 plaintiffs who own wells and property near the Fayetteville Works facility. The plaintiffs seek damages for nuisance allegedly caused by releases of certain PFCs from the site. The plaintiffs’ claims for medical monitoring, punitive damages, public nuisance, trespass, unjust enrichment, failure to warn, and negligent manufacture were dismissed.

Generally, site-related expenses related GenX claims are subject to the cost sharing arrangements as defined in the MOU.

Environmental
Accruals for environmental matters are recorded when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on current law and existing technologies. At March 31, 2021, the company had accrued obligations of $333 million for probable environmental remediation and restoration costs, including $56 million for the remediation of Superfund sites. These obligations are included in accrued and other current liabilities and other noncurrent obligations in the interim Condensed Consolidated Balance Sheet. This is management’s best estimate of the costs for remediation and restoration with respect to environmental matters for which the company has accrued liabilities, although it is reasonably possible that the ultimate cost with respect to these particular matters could range up to $577 million above the amount accrued at March 31, 2021. Consequently, it is reasonably possible that environmental remediation and restoration costs in excess of amounts accrued could have a material impact on the company’s results of operations, financial condition and cash flows. Inherent uncertainties exist in these estimates primarily due to unknown conditions, changing governmental regulations and legal standards regarding liability, and emerging remediation technologies for handling site remediation and restoration.

For a discussion of the allocation of environmental liabilities under the Chemours Separation Agreement and the Corteva Separation Agreement, see the previous discussion on page 22.

25
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

The above noted $333 million accrued obligations includes the following:
As of March 31, 2021
(In millions) Indemnification Asset
Accrual balance3,4
Potential exposure above amount accrued3
Environmental Remediation Stray Liabilities
Chemours related obligations - subject to indemnity1,2
$ 152  $ 152  $ 280 
Other discontinued or divested businesses obligations1
—  78  177 
Environmental remediation liabilities primarily related to DuPont - subject to indemnity from DuPont2
34  34  65 
Environmental remediation liabilities not subject to indemnity —  69  55 
Total $ 186  $ 333  $ 577 
1.Represents liabilities that are subject to the $200 million thresholds and sharing arrangements as discussed on page 22, under Corteva Separation Agreement.
2.The company has recorded an indemnification asset related to these accruals, including $30 million related to the Superfund sites.
3.Accrual balance represents management’s best estimate of the costs of remediation and restoration, although it is reasonably possible that the potential exposure, as indicated, could range above the amounts accrued, as there are inherent uncertainties in these estimates
4.Accrual balance excludes indemnification liabilities of $54 million to Chemours, related to the cost sharing arrangement under the MOU (see page 10).


NOTE 14 - STOCKHOLDERS' EQUITY

Share Buyback Plan
On June 26, 2019, Corteva, Inc. announced that the Board of Directors of Corteva, Inc. authorized a $1 billion share repurchase program to purchase Corteva, Inc.'s common stock, par value $0.01 per share, without an expiration date. The timing, price and volume of purchases will be based on market conditions, relevant securities laws and other factors.

During the three months ended March 31, 2021, the company purchased and retired 7,646,000 shares in the open market for a total cost of $350 million. During the three months ended March 31, 2020, the company purchased and retired 1,865,000 shares in the open market for a total cost of $50 million.

Shares repurchased pursuant to Corteva's share buyback plan are immediately retired upon purchase. Repurchased common stock is reflected as a reduction of stockholders' equity. The company's accounting policy related to its share repurchases is to reduce its common stock based on the par value of the shares and to reduce its retained earnings for the excess of the repurchase price over the par value. When Corteva has an accumulated deficit balance, the excess over the par value is applied to additional paid-in capital. When Corteva has retained earnings, the excess is charged entirely to retained earnings.

Noncontrolling Interest
Corteva, Inc. owns 100% of the outstanding common shares of EID. However, EID has preferred stock outstanding to third parties which is accounted for as a non-controlling interest in Corteva's interim Condensed Consolidated Balance Sheets. Each share of EID Preferred Stock - $4.50 Series and EID Preferred Stock - $3.50 Series issued and outstanding at the effective date of the Corteva Distribution remains issued and outstanding as to EID and was unaffected by the Corteva Distribution.

Below is a summary of the EID Preferred Stock at March 31, 2021, December 31, 2020, and March 31, 2020, which is classified as noncontrolling interests in Corteva's interim Condensed Consolidated Balance Sheets.
Shares in thousands Number of Shares
Authorized 23,000
$4.50 Series, callable at $120 1,673
$3.50 Series, callable at $102 700

26
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Other Comprehensive (Loss) Income
The changes and after-tax balances of components comprising accumulated other comprehensive loss are summarized below:
(In millions)
Cumulative Translation Adjustment1
Derivative Instruments Pension Benefit Plans Other Benefit Plans Unrealized Gain (Loss) on Investments Total
2020
Balance January 1, 2020 $ (1,944) $ 2  $ (1,247) $ (81) $ —  $ (3,270)
Other comprehensive (loss) income before reclassifications
(672) 1  (2) 3  —  (670)
Amounts reclassified from accumulated other comprehensive loss
—  5  2  —  —  7 
Net other comprehensive (loss) income
(672) 6  —  3  —  (663)
Balance March 31, 2020 $ (2,616) $ 8  $ (1,247) $ (78) $ —  $ (3,933)
2021          
Balance January 1, 2021 $ (1,970) $ (67) $ (1,433) $ 590  $ (10) $ (2,890)
Other comprehensive (loss) income before reclassifications
(403) 71  (4) 1  4  (331)
Amounts reclassified from accumulated other comprehensive loss
—  (6) 12  (158) 6  (146)
Net other comprehensive (loss) income
(403) 65  8  (157) 10  (477)
Balance March 31, 2021 $ (2,373) $ (2) $ (1,425) $ 433  $ —  $ (3,367)
1.The cumulative translation adjustment loss for the three months ended March 31, 2020 was primarily driven by the strengthening of the USD against the Brazilian Real (“BRL”) and the South African Rand ("ZAR"). The cumulative translation adjustment loss for the three months ended March 31, 2021 was primarily driven by strengthening of the USD against the Swiss Franc ("CHF"), Brazilian Real ("BRL") and European Euro.

The tax benefit (expense) on the net activity related to each component of other comprehensive (loss) income was as follows:
(In millions) Three Months Ended
March 31,
2021 2020
Derivative instruments $ (18) $ 5 
Pension benefit plans - net (2) (4)
Other benefit plans - net 49  — 
Benefit from income taxes related to other comprehensive (loss) income items $ 29  $ 1 


27
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

A summary of the reclassifications out of accumulated other comprehensive loss is provided as follows:
(In millions) Three Months Ended
March 31,
2021 2020
Derivative Instruments1:
$ (5) $ 7 
Tax benefit2
(1) (2)
After-tax $ (6) $ 5 
Amortization of pension benefit plans:
  Actuarial losses3,4
$ 14  $ 1 
  Settlement loss3,4
1  2 
Total before tax $ 15  $ 3 
Tax benefit2
(3) (1)
After-tax $ 12  $ 2 
Amortization of other benefit plans:
  Prior service benefit3,4
$ (230) $ — 
  Actuarial gains3,4
23  — 
Total before tax $ (207) $ — 
Tax benefit2
49  — 
After-tax $ (158) $ — 
Unrealized Loss on Investments4
$ 6  $ — 
Tax benefit2
—  — 
After-tax $ 6  $ — 
Total reclassifications for the period, after-tax $ (146) $ 7 
1.Reflected in cost of goods sold.
2.Reflected in provision for (benefit from) income taxes from continuing operations.
3.These accumulated other comprehensive (loss) income components are included in the computation of net periodic benefit credit of the company's pension and other benefit plans. See Note 15 - Pension Plans and Other Post Employment Benefits, for additional information.
4.Reflected in other income - net.

28
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 15 - PENSION PLANS AND OTHER POST EMPLOYMENT BENEFITS

The following sets forth the components of the company's net periodic benefit (credit) cost for defined benefit pension plans and other post employment benefits:
Three Months Ended
March 31,
(In millions) 2021 2020
Defined Benefit Pension Plans:
Service cost $ 7  $ 5 
Interest cost 91  141 
Expected return on plan assets (230) (251)
Amortization of unrecognized loss 14  1 
Settlement loss 1  2 
Net periodic benefit credit $ (117) $ (102)
Other Post Employment Benefits:
Service cost $ —  $ 1 
Interest cost 6  16 
Amortization of unrecognized loss 23  — 
Amortization of prior service benefit (230) — 
Net periodic benefit (credit) cost $ (201) $ 17 

NOTE 16 - FINANCIAL INSTRUMENTS

At March 31, 2021, the company had $1,602 million ($2,511 million and $1,536 million at December 31, 2020 and March 31, 2020, respectively) of held-to-maturity securities (primarily time deposits and money market funds) classified as cash equivalents, as these securities had maturities of three months or less at the time of purchase; and $49 million ($43 million and $10 million at December 31, 2020 and March 31, 2020, respectively) of held-to-maturity securities (primarily time deposits) classified as marketable securities as these securities had maturities of more than three months to less than one year at the time of purchase. The company’s investments in held-to-maturity securities are held at amortized cost, which approximates fair value. Additionally, at March 31, 2021, the company had $65 million ($226 million at December 31, 2020) of available-for-sale securities. The above noted securities are included in cash and cash equivalents, marketable securities, and other current assets in the interim Condensed Consolidated Balance Sheets.

Derivative Instruments
Objectives and Strategies for Holding Derivative Instruments
In the ordinary course of business, the company enters into contractual arrangements (derivatives) to reduce its exposure to foreign currency and commodity price risks. The company has established a variety of derivative programs to be utilized for financial risk management. These programs reflect varying levels of exposure coverage and time horizons based on an assessment of risk.

Derivative programs have procedures and controls and are approved by the Corporate Financial Risk Management Committee, consistent with the company's financial risk management policies and guidelines. Derivative instruments used are forwards, options, futures and swaps. The company has not designated any non-derivatives as hedging instruments.

The company's financial risk management procedures also address counterparty credit approval, limits and routine exposure monitoring and reporting. The counterparties to these contractual arrangements are major financial institutions and major commodity exchanges, and multinational grain exporters. The company is exposed to credit loss in the event of nonperformance by these counterparties. The company utilizes collateral support annex agreements with certain counterparties to limit its exposure to credit losses. The company anticipates performance by counterparties to these contracts and therefore no material loss is expected. Market and counterparty credit risks associated with these instruments are regularly reported to management.


29
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

The notional amounts of the company's derivative instruments were as follows:
Notional Amounts
(In millions)
March 31, 2021 December 31, 2020 March 31, 2020
Derivatives designated as hedging instruments:
Foreign currency contracts
$ 1,030  $ 1,164  $ 751 
Commodity contracts
$ 239  $ 383  $ 418 
Derivatives not designated as hedging instruments:
Foreign currency contracts $ 715  $ 647  $ 644 
Commodity contracts $ 154  $ —  $ 59 

Foreign Currency Risk
The company's objective in managing exposure to foreign currency fluctuations is to reduce earnings and cash flow volatility associated with foreign currency rate changes and to mitigate the exposure of certain investments in foreign subsidiaries against changes in the Euro/USD exchange rate. Accordingly, the company enters into various contracts that change in value as foreign exchange rates change to protect the value of its existing foreign currency-denominated assets, liabilities, commitments, investments and cash flows.

The company uses foreign exchange contracts to offset its net exposures, by currency, related to the foreign currency denominated monetary assets and liabilities of its operations. The primary business objective of this hedging program is to maintain an approximately balanced position in foreign currencies so that exchange gains and losses resulting from exchange rate changes, after related tax effects, are minimized. The company also uses foreign currency exchange contracts to offset a portion of the company’s exposure to certain forecasted transactions as well as the translation of foreign currency-denominated earnings. The company also uses commodity contracts to offset risks associated with foreign currency devaluation in certain countries.

Commodity Price Risk
Commodity price risk management programs serve to reduce exposure to price fluctuations on purchases of inventory such as corn and soybeans. The company enters into over-the-counter and exchange-traded derivative commodity instruments to hedge the commodity price risk associated with agricultural commodity exposures.

Derivatives Designated as Cash Flow Hedges
Commodity Contracts
The company enters into over-the-counter and exchange-traded derivative commodity instruments, including options, futures and swaps, to hedge the commodity price risk associated with agriculture commodity exposures.

While each risk management program has a different time maturity period, most programs currently do not extend beyond the next two years. Cash flow hedge results are reclassified into earnings during the same period in which the related exposure impacts earnings. Reclassifications are made sooner if it appears that a forecasted transaction is not probable of occurring.

The following table summarizes the after-tax effect of commodity contract cash flow hedges on accumulated other comprehensive loss:
Three Months Ended
March 31,
(In millions) 2021 2020
Beginning balance $ (16) $ 2 
Additions and revaluations of derivatives designated as cash flow hedges 30  (22)
Clearance of hedge results to earnings (4) 5 
Ending balance $ 10  $ (15)

At March 31, 2021, an after-tax net loss of $8 million is expected to be reclassified from accumulated other comprehensive loss into earnings over the next twelve months.

Foreign Currency Contracts
The company enters into forward contracts to hedge the foreign currency risk associated with forecasted transactions within certain foreign subsidiaries.
30
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)


While each risk management program has a different time maturity period, most programs currently do not extend beyond the next two years. Cash flow hedge results are reclassified into earnings during the same period in which the related exposure impacts earnings. Reclassifications are made sooner if it appears that a forecasted transaction is not probable of occurring.

The following table summarizes the after-tax effect of foreign currency cash flow hedges on accumulated other comprehensive loss:
Three Months Ended
March 31,
(In millions) 2021 2020
Beginning balance $ (17) $ — 
Additions and revaluations of derivatives designated as cash flow hedges 25  16 
Clearance of hedge results to earnings (2) — 
Ending balance $ 6  $ 16 

At March 31, 2021, an after-tax net gain of $6 million is expected to be reclassified from accumulated other comprehensive loss into earnings over the next twelve months.

Derivatives Designated as Net Investment Hedges
Foreign Currency Contracts
The company has designated €450 million of forward contracts to exchange EUR as net investment hedges. The purpose of these forward contracts is to mitigate FX exposure related to a portion of the company’s Euro net investments in certain foreign subsidiaries against changes in Euro/USD exchange rates. These hedges will expire and be settled in 2023, unless terminated early at the discretion of the company.

The company elected to apply the spot method in testing for effectiveness of the hedging relationship.

Derivatives not Designated in Hedging Relationships
Foreign Currency Contracts
The company uses foreign exchange contracts to reduce its net exposure, by currency, related to foreign currency-denominated monetary assets and liabilities of its operations so that exchange gains and losses resulting from exchange rate changes are minimized. The netting of such exposures precludes the use of hedge accounting; however, the required revaluation of the forward contracts and the associated foreign currency-denominated monetary assets and liabilities intends to achieve a minimal earnings impact, after taxes. The company also uses foreign currency exchange contracts to offset a portion of the company’s exposure to the translation of certain foreign currency-denominated earnings so that gains and losses on the contracts offset changes in the USD value of the related foreign currency-denominated earnings over the relevant aggregate period.

Commodity Contracts
The company utilizes options, futures and swaps that are not designated as hedging instruments to reduce exposure to commodity price fluctuations on purchases of inventory such as corn and soybeans. The company uses forward agreements, with durations less than one year, to buy and sell USD priced commodities in order to reduce its exposure to currency devaluation for a portion of its local currency cash balances. Counterparties to the forward sales agreements are multinational grain exporters and subject to the company’s financial risk management procedures.


31
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Fair Value of Derivative Instruments
Asset and liability derivatives subject to an enforceable master netting arrangement with the same counterparty are presented on a net basis in the interim Condensed Consolidated Balance Sheets. The presentation of the company's derivative assets and liabilities is as follows:
March 31, 2021
(In millions) Balance Sheet Location Gross
Counterparty and Cash Collateral Netting1
Net Amounts Included in the interim Condensed Consolidated Balance Sheet
Asset derivatives:      
Derivatives designated as hedging instruments:
Foreign currency contracts
Other current assets $ 38  $ —  $ 38 
Derivatives not designated as hedging instruments:
   
Foreign currency contracts Other current assets 52 (32) 20 
Total asset derivatives
  $ 90  $ (32) $ 58 
Liability derivatives:    
Derivatives designated as hedging instruments:
Foreign currency contracts Accrued and other current liabilities $ 16  $ —  $ 16 
Derivatives not designated as hedging instruments:
   
Foreign currency contracts Accrued and other current liabilities 46 (30) 16 
Total liability derivatives
  $ 62  $ (30) $ 32 

32
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

December 31, 2020
(In millions) Balance Sheet Location Gross
Counterparty and Cash Collateral Netting1
Net Amounts Included in the Condensed Consolidated Balance Sheet
Asset derivatives:      
Derivatives designated as hedging instruments:
Foreign currency contracts Other current assets $ 15  $ —  $ 15 
Derivatives not designated as hedging instruments:
   
Foreign currency contracts
Other current assets 40  (40) — 
Total asset derivatives
  $ 55  $ (40) $ 15 
Liability derivatives:    
Derivatives designated as hedging instruments:
Foreign currency contracts Accrued and other current liabilities $ 38  $ —  $ 38 
Derivatives not designated as hedging instruments:
   
Foreign currency contracts
Accrued and other current liabilities 97  (40) 57 
Total liability derivatives
  $ 135  $ (40) $ 95 
March 31, 2020
(In millions) Balance Sheet Location Gross
Counterparty and Cash Collateral Netting1
Net Amounts Included in the interim Condensed Consolidated Balance Sheet
Asset derivatives:      
Derivatives designated as hedging instruments:
Foreign currency contracts
Other current assets $ 36  $ —  $ 36 
Derivatives not designated as hedging instruments:
   
Foreign currency contracts
Other current assets 230  (110) 120 
Total asset derivatives
  $ 266  $ (110) $ 156 
Liability derivatives:    
Derivatives not designated as hedging instruments:
   
Foreign currency contracts
Accrued and other current liabilities $ 108  $ (103) $ 5 
Total liability derivatives
  $ 108  $ (103) $ 5 
1.    Counterparty and cash collateral amounts represent the estimated net settlement amount when applying netting and set-off rights included in master netting arrangements between the company and its counterparties and the payable or receivable for cash collateral held or placed with the same counterparty.


33
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Effect of Derivative Instruments
Amount of (Loss) Gain Recognized in OCI1 - Pre-Tax
Three Months Ended
March 31,
(In millions) 2021 2020
Derivatives designated as hedging instruments:
Net investment hedges:
Foreign currency contracts
$ 21  $ 9 
Cash flow hedges:
Foreign currency contracts
31  19 
 Commodity contracts 36  (34)
Total derivatives designated as hedging instruments $ 88  $ (6)
1.OCI is defined as other comprehensive income (loss).
Amount of Gain (Loss) Recognized in Income - Pre-Tax1
Three Months Ended
March 31,
(In millions) 2021 2020
Derivatives designated as hedging instruments:
Cash flow hedges:
Foreign currency contracts2
$ 1  $ — 
 Commodity contracts2
4  (7)
Total derivatives designated as hedging instruments
$ 5  $ (7)
Derivatives not designated as hedging instruments:
Foreign currency contracts3
$ 16  $ 165 
Foreign currency contracts2
2  — 
Commodity contracts2
(12) 9 
Total derivatives not designated as hedging instruments
6  174 
Total derivatives $ 11  $ 167 
1.For cash flow hedges, this represents the portion of the gain (loss) reclassified from accumulated OCI into income during the period.
2.Recorded in cost of goods sold.
3.Gain recognized in other income (expense) - net was partially offset by the related gain on the foreign currency-denominated monetary assets and liabilities of the company's operations. See Note 6 - Supplementary Information, for additional information.

Debt Securities
The company's investment in debt securities are classified as available-for-sale. At March 31, 2021, the fair value and amortized cost of the company's investments in debt securities with contractual maturities within one to five years was $65 million.

The estimated fair value of the available-for-sale securities as of March 31, 2021 and December 31, 2020 was determined using Level 1 inputs within the fair value hierarchy. Level 1 measurements were based on quoted market prices in active markets for identical assets and liabilities. The available-for-sale securities as of March 31, 2021 and December 31, 2020 are held by certain foreign subsidiaries in which the USD is not the functional currency. The fluctuations in foreign exchange are recorded in accumulated other comprehensive loss within the interim Consolidated Statements of Equity. These fluctuations are subsequently reclassified from accumulated other comprehensive loss to earnings in the period in which the marketable securities are sold and the gains and losses on these securities offset a portion of the foreign exchange fluctuations in earnings for the company.

34
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)


The following table provides the investing results from available-for-sale securities for the three months ended March 31, 2021:
Investing Results Three Months Ended
 March 31,
(In millions) 2021
Proceeds from sales of available-for-sale securities $ 161 
Gross realized losses (6)
Total $ 155 

The following table provides the fair value and gross unrealized losses of the company's investments in debt securities at March 31, 2021, aggregated by investment category:
March 31, 2021 12 months or more
(In millions) Fair value Gross unrealized losses
U.S. Treasuries $ 65  $ — 


NOTE 17 - FAIR VALUE MEASUREMENTS

The following tables summarize the basis used to measure certain assets and liabilities at fair value on a recurring basis:
March 31, 2021 Significant Other Observable Inputs
(In millions) Level 1 Level 2
Assets at fair value:
Marketable securities
$ —  $ 49 
Debt securities:
U.S. treasuries1
65 — 
Derivatives relating to:2
Foreign currency
—  90 
Total assets at fair value $ 65  $ 139 
Liabilities at fair value:
Derivatives relating to:2
Foreign currency
—  62 
Total liabilities at fair value $ —  $ 62 
December 31, 2020 Significant Other Observable Inputs
(In millions) Level 1 Level 2
Assets at fair value:
Marketable securities
$ —  $ 43 
Debt securities:
U.S. treasuries1
226 — 
Derivatives relating to:2
Foreign currency
—  55 
Total assets at fair value $ 226  $ 98 
Liabilities at fair value:
Derivatives relating to:2
Foreign currency
—  135 
Total liabilities at fair value $ —  $ 135 
35
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

March 31, 2020 Significant Other Observable Inputs (Level 2)
(In millions)
Assets at fair value:
Marketable securities
$ 10 
Derivatives relating to:2
Foreign currency
266 
Total assets at fair value $ 276 
Liabilities at fair value:
Derivatives relating to:2
Foreign currency
108 
Total liabilities at fair value $ 108 
1.    The company's investments in debt securities, which are available-for-sale, are included in "marketable securities" in the interim Condensed Consolidated Balance Sheets.
2. See Note 16 - Financial Instruments for the classification of derivatives in the interim Condensed Consolidated Balance Sheets.



NOTE 18 - SEGMENT INFORMATION
Corteva’s reportable segments reflects the manner in which its chief operating decision maker ("CODM") allocates resources and assesses performance, which is at the operating segment level (seed and crop protection). For purposes of allocating resources to the segments and assessing segment performance, segment operating EBITDA is the primary measure used by Corteva’s CODM. The company defines segment operating EBITDA as earnings (i.e., income (loss) from continuing operations before income taxes) before interest, depreciation, amortization, corporate expenses, non-operating (benefits) costs - net, foreign exchange gains (losses), and net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting, excluding the impact of significant items. Effective January 1, 2021, on a prospective basis, the company excludes from segment operating EBITDA net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting. Non-operating (benefits) costs - net consists of non-operating pension and other post-employment benefit (OPEB) costs, tax indemnification adjustments and environmental remediation and legal costs associated with legacy EID businesses and sites. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the company as pre-tax income or expense.

As of and for the Three Months Ended March 31,
(In millions)
Seed Crop Protection Total
2021      
Net sales $ 2,492  $ 1,686  $ 4,178 
Segment operating EBITDA $ 617  $ 321  $ 938 
Segment assets1
$ 24,799  $ 13,349  $ 38,148 
2020      
Net sales $ 2,455  $ 1,501  $ 3,956 
Segment operating EBITDA $ 581  $ 238  $ 819 
Segment assets1
$ 25,857  $ 13,251  $ 39,108 
1.    Segment assets at December 31, 2020 were $23,751 million and $13,099 million for Seed and Crop Protection, respectively.

 
36
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)


Reconciliation to interim Consolidated Financial Statements
Income from continuing operations after income taxes to segment operating EBITDA


(In millions)
Three Months Ended
March 31,
2021 2020
Income from continuing operations after income taxes $ 613  $ 281 
Provision for income taxes on continuing operations 178  127 
Income from continuing operations before income taxes 791  408 
Depreciation and amortization 304  283 
Interest income (21) (18)
Interest expense 7  10 
Exchange losses - net 35  61 
Non-operating benefits - net (311) (73)
Mark-to-market gains on certain foreign currency contracts not designated as hedges1
(1)
Significant items 100  123 
Corporate expenses 34  25 
Segment operating EBITDA $ 938  $ 819 
1.Effective January 1, 2021, on a prospective basis, the company excludes net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting. There was no activity in the three months ended March 31, 2020. Refer to page 48 for further discussion of the company’s Non-GAAP financial measures.

Segment assets to total assets (in millions)
March 31, 2021 December 31, 2020 March 31, 2020
Total segment assets $ 38,148  $ 36,850  $ 39,108 
Corporate assets 4,401  5,799  3,870 
Total assets $ 42,549  $ 42,649  $ 42,978 

Significant Pre-tax (Charges) Benefits Not Included in Segment Operating EBITDA
The three months ended March 31, 2021 and 2020, respectively, included the following significant pre-tax (charges) benefits which are excluded from segment operating EBITDA:
(In millions) Seed Crop Protection Corporate Total
For the Three Months Ended March 31, 2021
Restructuring and Asset Related Charges - Net 1
$ (21) $ (32) $ (47) $ (100)
Total $ (21) $ (32) $ (47) $ (100)
(In millions) Seed Crop Protection Corporate Total
For the Three Months Ended March 31, 2020
Restructuring and Asset Related Charges - Net 1
$ (10) $ (18) $ (42) $ (70)
Loss on Divestiture2
—  (53) —  (53)
Total $ (10) $ (71) $ (42) $ (123)
1.Includes Board approved restructuring plans and asset related charges as well as accelerated prepaid amortization expense. See Note 5 - Restructuring and Asset Related Charges - Net, to the interim Consolidated Financial Statements for additional information.
2.Includes a loss recorded in other income - net related to the sale of the La Porte site.
.






37
Item 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Cautionary Statements About Forward-Looking Statements

This report contains certain estimates and forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and may be identified by their use of words like “plans,” “expects,” “will,” “anticipates,” “believes,” “intends,” “projects,” “estimates,” "outlook," or other words of similar meaning. All statements that address expectations or projections about the future, including statements about Corteva’s strategy for growth, product development, regulatory approval, market position, liquidity, anticipated benefits of recent acquisitions, timing of anticipated benefits from restructuring actions, outcome of contingencies, such as litigation and environmental matters, expenditures, and financial results, as well as its expectations related to its separation of Corteva from DowDuPont and the agreements related thereto, are forward-looking statements.

Forward-looking statements and other estimates are based on certain assumptions and expectations of future events which may not be accurate or realized. Forward-looking statements and other estimates also involve risks and uncertainties, many of which are beyond Corteva’s control. While the list of factors presented below is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on Corteva’s business, results of operations and financial condition. Some of the important factors that could cause Corteva’s actual results to differ materially from those projected in any such forward-looking statements include: (i) failure to obtain or maintain the necessary regulatory approvals for some of Corteva’s products; (ii) failure to successfully develop and commercialize Corteva’s pipeline; (iii) effect of the degree of public understanding and acceptance or perceived public acceptance of Corteva’s biotechnology and other agricultural products; (iv) effect of changes in agricultural and related policies of governments and international organizations; (v) effect of competition and consolidation in Corteva’s industry; (vi) effect of competition from manufacturers of generic products; (vii) costs of complying with evolving regulatory requirements and the effect of actual or alleged violations of environmental laws or permit requirements; (viii) effect of climate change and unpredictable seasonal and weather factors; (ix) risks related to oil and commodity markets; (x) competitor’s establishment of an intermediary platform for distribution of Corteva's products; (xi) impact of Corteva's dependence on third parties with respect to certain of its raw materials or licenses and commercialization; (xii) effect of industrial espionage and other disruptions to Corteva’s supply chain, information technology or network systems; (xiii) effect of volatility in Corteva’s input costs; (xiv) failure to realize the anticipated benefits of the internal reorganizations taken by DowDuPont in connection with the spin-off of Corteva and other cost savings initiatives; (xv) failure to raise capital through the capital markets or short-term borrowings on terms acceptable to Corteva; (xvi) failure of Corteva’s customers to pay their debts to Corteva, including customer financing programs; (xvii) increases in pension and other post-employment benefit plan funding obligations; (xviii) risks related to the indemnification obligations of legacy EID liabilities in connection with the separation of Corteva; (xix) effect of compliance with laws and requirements and adverse judgments on litigation; (xx) risks related to Corteva’s global operations; (xxi) failure to effectively manage acquisitions, divestitures, alliances and other portfolio actions; (xxii) risks related to COVID-19; (xxiii) risks related to activist stockholders; (xxiv) Corteva’s intellectual property rights or defend against intellectual property claims asserted by others; (xxv) effect of counterfeit products; (xxvi) Corteva’s dependence on intellectual property cross-license agreements; and (xxvii) other risks related to the separation from DowDuPont.

Additionally, there may be other risks and uncertainties that Corteva is unable to currently identify or that Corteva does not currently expect to have a material impact on its business. Where, in any forward-looking statement or other estimate, an expectation or belief as to future results or events is expressed, such expectation or belief is based on the current plans and expectations of Corteva’s management and expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the expectation or belief will result or be achieved or accomplished. Corteva disclaims and does not undertake any obligation to update or revise any forward-looking statement, except as required by applicable law. A detailed discussion of some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-looking statements or other estimates is included in the “Risk Factors” section of Corteva’s Annual Report on Form 10-K, as modified by subsequent Quarterly Reports on Forms 10-Q and Current Reports on Form 8-K.



38
Recent Developments

COVID-19 Pandemic
On March 11, 2020, the World Health Organization (“WHO”) declared the novel coronavirus disease (“COVID-19”) a pandemic. The global health crisis caused by COVID-19 and the related government actions and stay at home orders have negatively impacted economic activity and increased political instability across the globe. Since the crisis began Corteva has engaged its global Integrated Health Services Pandemic & Infectious Disease Team to take actions and implement guidelines and protocols in response to the COVID-19 pandemic described in its 2020 Annual Report, Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations, COVID-19 Pandemic.

When COVID-19 is demonstrably contained, the company anticipates a rebound in economic activity, depending on the rate, pace, and effectiveness of the containment efforts deployed by various national, state, and local governments, vaccination rates, and the ability of COVD-19 variants to overcome containment efforts, available vaccines, and medical treatments. Corteva will continue to actively monitor the situation and may take further actions altering its business operations that it determines are in the best interests of its stakeholders, or as required by federal, state, or local authorities. It is not clear what the potential effects any such alterations or modifications may have on the company's business, including the effects on its customers, employees, and prospects, or on its financial results for 2021 and beyond. With the ongoing volatility in global markets, the company will continue to monitor various factors that could impact earnings and cash flows of the business, including, but not limited to the inflation of, or unavailability of raw material inputs and transportation and logistics services, currency fluctuations, expectations of future planted area (as influenced by consumer demand, ethanol markets and government policies and regulations), trade and purchasing of commodities globally and relative commodity prices.

2021 Restructuring Actions
On February 1, 2021, Corteva approved restructuring actions designed to right-size and optimize footprint and organizational structure according to the business needs in each region with the focus on driving continued cost improvement and productivity. As a result of these actions, the company expects to record total pre-tax restructuring charges of approximately $130 million to $170 million, comprised of approximately $40 million to $50 million of severance and related benefit costs, $40 million to $60 million of asset related charges, $10 million to $15 million of asset retirement obligations and $40 million to $45 million of costs related to contract terminations (contract terminations includes early lease terminations). Future cash payments related to this charge are anticipated to be approximately $80 million to $100 million, primarily related to the payment of severance and related benefits, asset retirement obligations, and costs related to contract terminations. The restructuring actions associated with this charge are expected to be substantially complete in 2021.

During the three months ended March 31, 2021, the company recorded pre-tax charges of $89 million, recognized in restructuring and asset related charges - net in the company's interim Consolidated Statement of Operations, primarily related to the payment of severance and related benefits and contract termination charges.

The 2021 Restructuring Actions are expected to contribute to the company’s ongoing cost and productivity improvement efforts through achieving an estimated $70 million of savings on a run rate basis by 2023. See Note 5 - Restructuring and Asset Related Charges - Net, to the interim Consolidated Financial Statements for additional information.

Share Buyback Plan
On June 26, 2019, Corteva, Inc. announced that its Board of Directors authorized a $1 billion share repurchase program to purchase Corteva, Inc.'s common stock, par value $0.01 per share, without an expiration date. The company expects to complete the share repurchase program in 2021. The timing, price and volume of purchases will be based on market conditions, relevant securities laws and other factors. During the three months ended March 31, 2021, the company purchased and retired 7,646,000 shares in the open market for a total cost of $350 million. During the three months ended March 31, 2020, the company purchased and retired 1,865,000 shares in the open market for a total cost of $50 million.

39
Overview

The following is a summary of results from continuing operations for the three months ended March 31, 2021:

•The company reported net sales of $4,178 million, up 6 percent versus the same quarter last year, reflecting a 3 percent increase in volume and a 3 percent increase in price. Volume and price gains were driven by continued penetration of new products, coupled with favorable overall market fundamentals.

•Cost of goods sold ("COGS") totaled $2,420 million in the first quarter of 2021, up from $2,269 million in the first quarter of 2020, primarily driven by increased volumes and higher input costs, partially offset by ongoing cost and productivity actions.

•Restructuring and asset related charges - net were $100 million in the first quarter of 2021, an increase from $70 million in the first quarter of 2020. The charges in the first quarter of 2021 primarily relate to severance and related benefit costs, asset related charges, and contract termination charges associated with 2021 Restructuring Actions.

•Income from continuing operations after income taxes was $613 million, as compared to $281 million in the same quarter last year.

•Operating EBITDA was $904 million for the three months ended March 31, 2021, up from $794 million for the three months ended March 31, 2020, primarily driven by strong price execution and volume gains, which collectively more than offset cost headwinds. The company experienced market-driven cost headwinds in the quarter, including cost increases in freight and logistics, as well as raw materials. These headwinds were partially offset by the company’s ongoing execution on its productivity programs. Refer to page 48 for further discussion of the company's Non-GAAP financial measures.

In addition to the financial highlights above, the following events occurred during or subsequent to the three months ended March 31, 2021:

•The company returned approximately $450 million to shareholders during the three months ended March 31, 2021 under its previously announced share repurchase program and through common stock dividends.






40
Selected Financial Data
In millions, except per share amounts Three Months Ended
March 31,
2021 2020
Net sales $ 4,178  $ 3,956 
Cost of goods sold $ 2,420  $ 2,269 
Percent of net sales 58  % 57  %
Research and development expense $ 281  $ 280 
Percent of net sales 7  % 7  %
Selling, general and administrative expenses $ 733  $ 757 
Percent of net sales 18  % 19  %
Effective tax rate on continuing operations 22.5  % 31.1  %
Income from continuing operations after income taxes $ 613  $ 281 
Income from continuing operations available to Corteva common stockholders $ 610  $ 271 
Basic earnings per share of common stock from continuing operations $ 0.82  $ 0.36 
Diluted earnings per share of common stock from continuing operations $ 0.81  $ 0.36 

41
Results of Operations

Net Sales
Net sales were $4,178 million and $3,956 million for the three months ended March 31, 2021 and 2020, respectively. Volume and local price both increased 3 percent versus the prior-year period, primarily driven by the ongoing penetration of new products coupled with favorable overall market fundamentals. Gains were reported in most regions, led by double-digit growth in Latin America.

  Three Months Ended
March 31,
2021 2020
Net Sales
($ Millions) 		% Net Sales
($ Millions) 		%
Worldwide $ 4,178  100  % $ 3,956  100  %
North America1
1,743  42  % 1,765  45  %
EMEA2
1,602  38  % 1,467  37  %
Latin America
518  12  % 434  11  %
Asia Pacific
315  8  % 290  7  %
Q1 2021 vs. Q1 2020 Percent Change Due To:
Net Sales Change Local Price & Portfolio /
$ In millions $ % Product Mix Volume Currency Other
North America1
$ (22) (1) % 1  % (3) % 1  % —  %
EMEA2
135  9  % 3  % 3  % 3  % —  %
Latin America 84  19  % 14  % 24  % (19) % —  %
Asia Pacific 25  9  % 3  % 6  % 4  % (4) %
Total $ 222  6  % 3  % 3  % —  % —  %
1.Represents U.S. & Canada.
2.Europe, Middle East, and Africa ("EMEA").

Cost of Goods Sold
COGS was $2,420 million (58 percent of net sales) and $2,269 million (57 percent of net sales) for the three months ended March 31, 2021 and 2020, respectively. The increase was primarily driven by higher input costs in both crop protection and seed. Also, the company experienced higher seed freight costs due to lower service capacity combined with an increase in volumes, all partially offset by ongoing cost and productivity actions.

Research and Development Expense
R&D expense was $281 million (7 percent of net sales) and $280 million (7 percent of net sales) for the three months ended March 31, 2021 and 2020, respectively. R&D expense was essentially flat, as compared to prior year, as increases in spending to support new product launches were offset by ongoing cost and productivity actions.

Selling, General and Administrative Expenses
SG&A expenses were $733 million (18 percent of net sales) and $757 million (19 percent of net sales) for the three months ended March 31, 2021 and 2020, respectively. The decrease was primarily driven by lower bad debt expense due to a reduction in the reserve percentage used based on improvements in the loss history, lower travel expense due to COVID-19 related restrictions put into place late in the first quarter of 2020, and favorable currency, partially offset by higher commission expense due to an increase in sales.

Amortization of Intangibles
Intangible asset amortization was $183 million and $163 million for the three months ended March 31, 2021 and 2020, respectively. The increase was primarily driven by amortization of the trade name asset that was changed from indefinite lived intangible asset to definite lived in the fourth quarter of 2020. See Note 11 - Other Intangible Assets, to the interim Consolidated Financial Statements for additional information.



42
Restructuring and Asset Related Charges - Net
Restructuring and asset related charges - net were $100 million and $70 million for the three months ended March 31, 2021 and 2020, respectively. The charges in the first quarter of 2021 primarily relate to severance and related benefit costs, contract termination charges, and asset related charges associated with 2021 Restructuring Actions. The charges in the first quarter of 2020 primarily relate to severance and related benefit costs and asset related charges under the Execute to Win Productivity Program.

In addition, during the three months ended March 31, 2021 and 2020, the company recognized $7 million and $10 million, respectively, in restructuring and asset related charges, net in the interim Consolidated Statement of Operations, from non-cash accelerated prepaid royalty amortization expense related to Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits.

See Note 5 - Restructuring and Asset Related Charges, Net, to the interim Consolidated Financial Statements for additional information.

Other Income - Net
Other income - net was $337 million and $1 million for the three months ended March 31, 2021 and 2020, respectively. The increase was primarily due to an increase in non-operating pension and other post employment benefit credit, driven by the December 2020 OPEB plan amendments as discussed in the 2020 Annual Report. In addition, Other income - net for the quarter ended March 31, 2020 includes a $(53) million loss on the sale of the La Porte site. See Note 6 - Supplementary Information, to the interim Consolidated Financial Statements for additional information.

Pre-tax net exchange losses were $35 million and $61 million for the three months ended March 31, 2021 and 2020, respectively. The company routinely uses forward exchange contracts to offset its net exposures, by currency denominated monetary assets and liabilities of its operations. The objective of this program is to maintain an approximately balanced position in foreign currencies in order to minimize, on an after-tax basis, the effects of exchange rate changes. The net pre-tax exchange gains and losses are recorded in other income - net and the related tax impact is recorded in provision for (benefit from) income taxes on continuing operations in the interim Consolidated Statement of Operations.

Interest Expense
Interest expense was $7 million and $10 million for the three months ended March 31, 2021 and 2020, respectively. The change was primarily driven by lower average commercial paper balances and lower interest rates, partially offset by higher average long-term borrowings.

Provision for Income Taxes on Continuing Operations
The company’s provision for income taxes on continuing operations was $178 million for the three months ended March 31, 2021 on pre-tax income from continuing operations of $791 million, resulting in an effective tax rate of 22.5 percent. The effective tax rate was unfavorably impacted by the tax impact of certain net exchange losses recognized on the re-measurement of the net monetary asset positions which were not tax-deductible in their local jurisdictions, as well as geographic mix of earnings. Those unfavorable impacts were partially offset by $(7) million of net tax benefits associated with changes in accruals for certain prior year tax positions in various jurisdictions, as well as tax benefits related to the issuance of stock-based compensation.
The company’s provision for income taxes on continuing operations was $127 million for the three months ended March 31, 2020 on pre-tax income from continuing operations of $408 million, resulting in an effective tax rate of 31.1 percent. The effective tax rate was unfavorably impacted by the tax impact of certain net exchange losses recognized on the re-measurement of the net monetary asset positions which were not tax-deductible in their local jurisdictions, as well as tax charges related to the issuance of stock-based compensation.

EID Analysis of Operations
As discussed in Note 1 - Basis of Presentation, to the EID Consolidated Financial Statements, EID is a subsidiary of Corteva, Inc. and continues to be a reporting company, subject to the requirements of the Exchange Act. The below relates to EID only and is presented to provide an Analysis of Operations, only for the differences between EID and Corteva, Inc.


43
Interest Expense
EID’s interest expense was $22 million and $42 million for the three months ended March 31, 2021 and 2020, respectively. The change was primarily driven by the items noted on page 43, under the header "Interest Expense," and by lower interest expense incurred on the related party loan between EID and Corteva, Inc. See Note 2 - Related Party Transactions, to the EID Consolidated Financial Statements for further information.

Provision for Income Taxes on Continuing Operations
EID’s provision for income taxes on continuing operations was $174 million for three months ended March 31, 2021 on pre-tax income from continuing operations of $776 million, resulting in an effective tax rate of 22.4 percent. EID’s provision for income taxes on continuing operations was $119 million for the three months ended March 31, 2020 on pre-tax income from continuing operations of $376 million, resulting in an effective tax rate of 31.6 percent.

EID’s effective tax rates for the three months ended March 31, 2021 and 2020 were driven by the items noted on page 43, under the header “Provision for Income Taxes on Continuing Operations” and a tax benefit related to the interest expense incurred on the related party loan between EID and Corteva, Inc. See Note 2 - Related Party Transactions, to the EID Consolidated Financial Statements for further information.

Corporate Outlook
The company is increasing its net sales outlook for 2021, and expects an approximate 3 – 4 percent increase in net sales. Additionally, the company is reaffirming its previous 2021 Corporate Outlook on Operating EBITDA and Operating Earnings Per Share, refer to the 2020 Annual Report, and expects an increase of approximately 15 - 20 percent and 23 - 30 percent, respectively.

Corteva is not able to reconcile its forward-looking non-GAAP financial measures to its most comparable U.S. GAAP financial measures, as it is unable to predict with reasonable certainty items outside of the company’s control, such as Significant Items, without unreasonable effort (refer to page 49 for Significant Items recorded in the three months ended March 31, 2021 and 2020). During 2021, the company expects to record $130 million to $170 million for the 2021 Restructuring Actions and approximately $130 million for non-cash accelerated prepaid royalty amortization expense as restructuring and asset related charges. See Note 5 - Restructuring and Asset Related Charges - Net, to the interim Consolidated Financial Statements for additional information on the company’s 2021 Restructuring Actions and accelerated prepaid royalty amortization.


Recent Accounting Pronouncements
See Note 2 - Recent Accounting Guidance, to the interim Consolidated Financial Statements for a description of recent accounting pronouncements.


44
Segment Reviews
The company operates in two reportable segments: Seed and Crop Protection.

Seed
The company’s seed segment is a global leader in developing and supplying advanced germplasm and traits that produce optimum yield for farms around the world. The segment is a leader in many of the company’s key seed markets, including North America corn and soybeans, Europe corn and sunflower, as well as Brazil, India, South Africa and Argentina corn. The segment offers trait technologies that improve resistance to weather, disease, insects and herbicides used to control weeds, and trait technologies that enhance food and nutritional characteristics. In addition, the segment provides digital solutions that assist farmer decision-making with a view to optimize product selection and, ultimately, help maximize yield and profitability.

Crop Protection
The crop protection segment serves the global agricultural input industry with products that protect against weeds, insects and other pests, and disease, and that improve overall crop health both above and below ground via nitrogen management and seed-applied technologies. The segment offers crop protection solutions that provide farmers the tools they need to improve productivity and profitability, and help keep fields free of weeds, insects and diseases. The segment is a leader in global herbicides, insecticides, nitrogen stabilizers and pasture and range management herbicides.

Summarized below are comments on individual segment net sales and segment operating EBITDA for the three months ended March 31, 2021 compared with the same period in 2020. The company defines segment operating EBITDA as earnings (i.e., income from continuing operations before income taxes) before interest, depreciation, amortization, corporate expenses, non-operating costs-net, foreign exchange gains (losses), and net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting, excluding the impact of significant items. Non-operating costs-net consists of non-operating pension and other post-employment benefit (OPEB) credits, tax indemnification adjustments and environmental remediation and legal costs associated with legacy EID businesses and sites. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the company as pre-tax income or expense. Beginning January 1, 2021, the company excludes net unrealized gains or losses from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting. See Note 18 - Segment Information, to the interim Consolidated Financial Statements for details related to significant pre-tax benefits (charges) excluded from segment operating EBITDA. All references to prices are based on local price unless otherwise specified.

A reconciliation of segment operating EBITDA to income from continuing operations after income taxes for the three months ended March 31, 2021 and 2020 is included in Note 18 - Segment Information, to the interim Consolidated Financial Statements.
Seed Three Months Ended
March 31,
In millions 2021 2020
Net sales $ 2,492  $ 2,455 
Segment operating EBITDA
$ 617  $ 581 
Seed Q1 2021 vs. Q1 2020 Percent Change Due To:
Net Sales Change Local Price & Portfolio /
$ In millions $ % Product Mix Volume Currency Other
North America $ (80) (6) % (1) % (6) % 1  % —  %
EMEA 66  7  % 3  % 2  % 2  % —  %
Latin America 58  27  % 9  % 39  % (21) % —  %
Asia Pacific (7) (10) % 5  % (12) % (3) % —  %
Total $ 37  2  % 2  % 1  % (1) % —  %
45
Seed Q1 2021 vs. Q1 2020 Percent Change Due To:
Net Sales Change Local Price & Portfolio /
$ In millions $ % Product Mix Volume Currency Other
Corn $ 24  1  % 2  % —  % (1) % —  %
Soybeans (4) (2) % (4) % —  % 2  % —  %
Other oilseeds 48  19  % 4  % 18  % (3) % —  %
Other (31) (19) % (5) % (12) % (2) % —  %
Total $ 37  2  % 2  % 1  % (1) % —  %

Seed
Seed net sales were $2,492 million in the first quarter of 2021, up 2 percent from $2,455 million in the first quarter of 2020. Gains were driven by a 2 percent increase in local price and a 1 percent increase in volume, partially offset by a 1 percent impact from currency.

Pricing gains were driven by strong adoption of new Seed technology, including price execution in EMEA and Latin America, with corn price up 2% globally. Volume growth was driven by record corn and sunflower volume in EMEA due to a shift in customer demand on local supply concerns and an early start to the spring, coupled with strong Safrinha sales in Brazil and early demand in other parts of Latin America. Gains were partially offset by impact of seasonal timing of deliveries in North America. Unfavorable currency impacts, led by the Brazilian Real, were partially offset by favorable impacts from the Euro.

Segment operating EBITDA was $617 million in the first quarter of 2021, up 6 percent from $581 million in the first quarter of 2020. Price execution, lower SG&A driven by an improvement in bad debt, a gain on the remeasurement of an equity investment and ongoing cost and productivity actions more than offset higher input costs from unfavorable yields on European corn, higher freight costs and the unfavorable impact of currency. Segment operating EBITDA margin improved by more than 100 basis points versus the prior-year period.

Crop Protection Three Months Ended
March 31,
In millions 2021 2020
Net sales $ 1,686  $ 1,501 
Segment Operating EBITDA
$ 321  $ 238 
Crop Protection Q1 2021 vs. Q1 2020 Percent Change Due To:
Net Sales Change Local Price & Portfolio /
$ In millions $ % Product Mix Volume Currency Other
North America
$ 58  12  % 6  % 5  % 1  % —  %
EMEA
69  12  % 3  % 4  % 5  % —  %
Latin America
26  12  % 18  % 10  % (16) % —  %
Asia Pacific
32  14  % 2  % 12  % 5  % (5) %
Total $ 185  12  % 6  % 6  % 1  % (1) %
Crop Protection Q1 2021 vs. Q1 2020 Percent Change Due To:
Net Sales Change Local Price & Portfolio /
$ In millions $ % Product Mix Volume Currency Other
Herbicides $ 163  20  % 5  % 12  % 3  % —  %
Insecticides 7  2  % 8  % (4) % (2) % —  %
Fungicides 32  14  % 5  % 14  % (1) % (4) %
Other (17) (24) % (1) % (19) % (4) % —  %
Total $ 185  12  % 6  % 6  % 1  % (1) %


46

Crop Protection
Crop protection net sales were $1,686 million in the first quarter of 2021, up 12 percent from $1,501 million in the first quarter of 2020. Gains were driven by 6 percent increases in volume and price, respectively, and a 1 percent favorable impact from currency, partially offset by a 1 percent impact from portfolio.

Volume gains were driven by strong demand for new products globally, including ArylexTM, EnlistTM, and RinskorTM herbicides and IsoclastTM and PyraxaltTM insecticides. These volume gains were partially offset by an approximate $70 million impact from the company's decision to phase out select low-margin, generic products. Local price rose due to increases in Latin America, coupled with favorable product mix globally and strategic price increases in North America. Favorable currency impacts primarily from the Euro more than offset unfavorable impacts from the Brazilian Real. The portfolio impact was driven by prior-year divestitures in Asia Pacific.

Segment operating EBITDA was $321 million in the first quarter of 2021, up 35 percent from $238 million in the first quarter of 2020. Price and volume gains and ongoing cost and productivity actions more than offset higher input costs, including raw materials costs. Segment operating EBITDA margin improved by more than 300 basis points versus prior-year.

While the company has experienced some supply chain challenges and higher costs during the quarter ended March 31, 2021, as a result of freight and logistic service capacities remaining contracted and not yet having returned to pre-pandemic levels and weather-related events in the Gulf Coast, its supply chain strategies have to-date largely enabled availability of product and deliveries to customers.

47
Non-GAAP Financial Measures
The company presents certain financial measures that do not conform to U.S. GAAP and are considered non-GAAP measures. These measures include Operating EBITDA and operating earnings per share. Management uses these measures internally for planning and forecasting, including allocating resources and evaluating incentive compensation. Management believes that these non-GAAP measures best reflect the ongoing performance of the company during the periods presented and provide more relevant and meaningful information to investors as they provide insight with respect to ongoing operating results of the company and a more useful comparison of year over year results. These non-GAAP measures supplement the company's U.S. GAAP disclosures and should not be viewed as an alternative to U.S. GAAP measures of performance. Furthermore, such non-GAAP measures may not be consistent with similar measures provided or used by other companies. Reconciliations for these non-GAAP measures to U.S. GAAP are provided below.

Operating EBITDA is defined as earnings (i.e., income from continuing operations before income taxes) before interest, depreciation, amortization, non-operating (benefits) costs - net, foreign exchange gains (losses), and net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting, excluding the impact of significant items. Non-operating (benefits) costs - net consists of non-operating pension and OPEB credits, tax indemnification adjustments and environmental remediation and legal costs associated with legacy businesses and sites of Historical DuPont. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the company as pre-tax income or expense. Operating earnings per share is defined as "Earnings per common share from continuing operations - diluted" excluding the after-tax impact of significant items, the after-tax impact of non-operating (benefits) costs - net, the after-tax impact of amortization expense associated with intangible assets existing as of the Separation from DowDuPont, and the after-tax impact of net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting. Although amortization of the company's intangible assets is excluded from these non-GAAP measures, management believes it is important for investors to understand that such intangible assets contribute to revenue generation. Amortization of intangible assets that relate to past acquisitions will recur in future periods until such intangible assets have been fully amortized. Any future acquisitions may result in amortization of additional intangible assets. Net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting represents the non-cash net gain (loss) from changes in fair value of certain undesignated foreign currency derivative contracts. Upon settlement, which is within the same calendar year of execution of the contract, the realized gain (loss) from the changes in fair value of the non-qualified foreign currency derivative contracts will be reported in the relevant non-GAAP financial measures, allowing quarterly results to reflect the economic effects of the foreign currency derivative contracts without the resulting unrealized mark to fair value volatility.

Reconciliation of Income from Continuing Operations after Income Taxes to Operating EBITDA
Three Months Ended
March 31,
(In millions) 2021 2020
Income from continuing operations after income taxes (GAAP)
$ 613  $ 281 
Provision for income taxes on continuing operations 178  127 
Income from continuing operations before income taxes (GAAP) 791  408 
Depreciation and amortization 304  283 
Interest income (21) (18)
Interest expense 7  10 
Exchange losses - net
35  61 
Non-operating benefits - net (311) (73)
Mark-to-market gains on certain foreign currency contracts not designated as hedges1
(1)
Significant items charge 100  123 
Operating EBITDA (Non-GAAP) $ 904  $ 794 
1.Effective January 1, 2021, on a prospective basis, the company excludes net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting. There was no activity in the three months ended March 31, 2020.


48
Significant Items
Three Months Ended
March 31,
(In millions) 2021 2020
Restructuring and asset related charges - net $ (100) $ (70)
Loss on divestiture —  (53)
Total pretax significant items charge (100) (123)
Total tax benefit impact of significant items1
23  23 
Tax only significant item benefit2
—  (19)
Total significant items charge, after tax $ (77) $ (119)
1.Unless specifically addressed above, the income tax effect on significant items was calculated based upon the enacted tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment.
2.The three months ended March 31, 2020 includes an after tax charge related to the impact of a state tax valuation allowance in the U.S. based on a change in judgment about the realizability of a deferred tax asset.

Reconciliation of Income from Continuing Operations Attributable to Corteva and Earnings Per Share of Common Stock from Continuing Operations - Diluted to Operating Earnings and Operating Earnings Per Share
Three Months Ended
March 31,
(In millions) 2021 2020
Income from continuing operations attributable to Corteva (GAAP)
$ 610  $ 271 
Less: Non-operating benefits - net, after tax 237  57 
Less: Amortization of intangibles (existing as of Separation), after tax (143) (114)
Less: Mark-to-market gains on certain foreign currency contracts not designated as hedges, after tax1
1 
Less: Significant items charge, after tax (77) (119)
Operating Earnings (Non-GAAP) $ 592  $ 447 
Three Months Ended
March 31,
2021 2020
Earnings per share of common stock from continuing operations - diluted (GAAP)
$ 0.81  $ 0.36 
Less: Non-operating benefits - net, after tax 0.31  0.08 
Less: Amortization of intangibles (existing as of Separation), after tax (0.19) (0.15)
Less: Mark-to-market gains on certain foreign currency contracts not designated as hedges, after tax1
— 
Less: Significant items charge, after tax (0.10) (0.16)
Operating Earnings Per Share (Non-GAAP) $ 0.79  $ 0.59 
Diluted Shares Outstanding (in millions)
749.6  752.5 
1.Effective January 1, 2021, on a prospective basis, the company excludes net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting. There was no activity in the three months ended March 31, 2020.

49
Liquidity and Capital Resources
Information related to the company's liquidity and capital resources can be found in the company’s 2020 Annual Report, Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations, Liquidity & Capital Resources. The discussion below provides the updates to this information for the three months ended March 31, 2021.
(In millions) March 31, 2021 December 31, 2020 March 31, 2020
Cash, cash equivalents and marketable securities $ 2,518  $ 3,795  $ 1,973 
Total debt $ 2,352  $ 1,105  $ 2,610 

The company's cash, cash equivalents and marketable securities at March 31, 2021, December 31, 2020, and March 31, 2020 were $2,518 million, $3,795 million and $1,973 million, respectively. Total debt at March 31, 2021, December 31, 2020, and March 31, 2020 was $2,352 million, $1,105 million, and $2,610 million, respectively. The increase in debt balances from December 31, 2020 was primarily due to funding the company’s seasonal working capital needs. See further information in Note 12 - Short-Term Borrowings, Long-Term Debt and Available Credit Facilities, to the interim Consolidated Financial Statements.

The company believes its ability to generate cash from operations and access to capital markets and commercial paper markets will be adequate to meet anticipated cash requirements to fund its operations, including seasonal working capital, capital spending and pension obligations. Corteva's strong financial position, liquidity and credit ratings will provide access as needed to capital markets and commercial paper markets to fund seasonal working capital needs. The company's liquidity needs can be met through a variety of sources, including cash provided by operating activities, commercial paper, syndicated credit lines, bilateral credit lines, long-term debt markets, bank financing and committed receivable repurchase facilities. Corteva considers the borrowing costs and lending terms when selecting the source to fund its operations and working capital needs. During the three months ended March 31, 2021, the company has experienced increased costs for steel and other materials used in various capital expenditures and capacity expansion projects, and expects this trend to continue. This has been due, in part to, rising demand from the economic recovery from the lifting of COVID-19 pandemic restrictions and government stimulus in some regions, while the supply for certain materials have not returned to pre-pandemic levels.

The company had access to approximately $6.4 billion at March 31, 2021 and December 31, 2020, respectively and $5.8 billion at March 31, 2020, in committed and uncommitted unused credit lines. In addition to the unused credit facilities, the company has a $1 billion 2021 Repurchase Facility (as defined below). These facilities provide support to meet the company’s short-term liquidity needs and for general corporate purposes which may include funding of discretionary and nondiscretionary contributions to certain benefit plans, severance payments, repayment and refinancing of debt, working capital, capital expenditures, repurchases and redemptions of securities, and funding Corteva's costs and expenses.

In March 2020, the company drew down $500 million under the three year revolving credit facility to finance its short term liquidity needs as a result of the volatility and increased borrowing costs of commercial paper resulting from the unstable market conditions caused by the COVID-19 pandemic, and repaid that borrowing in full in June 2020. The Revolving Credit Facilities contain customary representations and warranties, affirmative and negative covenants and events of default that are typical for companies with similar credit ratings. The Revolving Credit Facilities also contain a financial covenant requiring that the ratio of total indebtedness to total capitalization for Corteva and its consolidated subsidiaries not exceed 0.60. At March 31, 2021 the company was in compliance with these covenants.

The company's indenture covenants include customary limitations on liens, sale and leaseback transactions, and mergers and consolidations affecting manufacturing plants, mineral producing properties or research facilities located in the U.S. and the consolidated subsidiaries owning such plants, properties and facilities subject to certain limitations. The outstanding long-term debt also contains customary default provisions.
The company has meaningful seasonal working capital needs based in part on providing financing to its customers. Working capital is funded through multiple methods including cash, commercial paper, the 2021 Repurchase Facility, the Revolving Credit Facilities, and factoring.

In February 2021, in line with seasonal working capital requirements, the company entered into a committed receivable repurchase agreement of up to $1.0 billion (the "2021 Repurchase Facility") which expires in December 2021. Under the 2021 Repurchase Facility, Corteva may sell a portfolio of available and eligible outstanding customer notes receivables to participating institutions and simultaneously agree to repurchase at a future date. See further discussion of this facility in Note 12 - Short-Term Borrowings, Long-Term Debt and Available Credit Facilities, to the interim Consolidated Financial Statements.

50
The company has factoring agreements with third-party financial institutions to sell its trade receivables under both recourse and non-recourse agreements in exchange for cash proceeds in an effort to reduce its receivables risk. For arrangements that include an element of recourse, the company provides a guarantee of the trade receivables in the event of customer default. Refer to Note 9 - Accounts and Notes Receivable, Net, to the interim Consolidated Financial Statements for more information.
The company also organizes agreements with third-party financial institutions who directly provide financing for select customers of the company's seed and crop protection products in each region. Terms of the third-party loans are less than a year and programs are renewed on an annual basis. In some cases, the company guarantees a portion of the extension of such credit to such customers. Refer to Note 13 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements for more information on the company’s guarantees.

The company's cash, cash equivalents and marketable securities at March 31, 2021, December 31, 2020, and March 31, 2020 are $2.5 billion, $3.8 billion, and $2.0 billion respectively, of which $2.4 billion at March 31, 2021, $3.1 billion at December 31, 2020, and $1.5 billion at March 31, 2020 was held by subsidiaries in foreign countries, including United States territories. The 2017 Tax Cuts and Jobs Act ("The Act") required companies to pay a one-time transition tax on the untaxed earnings of foreign subsidiaries. Upon actual repatriation, such earnings could be subject to withholding taxes, foreign and/or U.S. state income taxes, and taxes resulting from the impact of foreign currency movements. The Act also introduced a 100 percent dividends received deduction regarding earnings of foreign subsidiaries. The cash held by foreign subsidiaries is generally used to finance the subsidiaries' operational activities and future foreign investments. At March 31, 2021, management believed that sufficient liquidity is available in the U.S. with global operating cash flows, borrowing capacity from existing committed credit facilities, and access to capital markets and commercial paper markets.

Summary of Cash Flows
Cash used for operating activities was $1,950 million for the three months ended March 31, 2021 compared to $1,930 million for the three months ended March 31, 2020. The change in cash used for operating activities was driven by an increase in working capital requirements.

Cash provided by (used for) investing activities was $36 million for the three months ended March 31, 2021 compared to $(130) million for the three months ended March 31, 2020. The change was primarily due to higher net proceeds from investments in available-for-sale securities, partly offset by higher capital expenditures.

Cash provided by financing activities was $0.8 billion for the three months ended March 31, 2021 compared to $2.3 billion for the three months ended March 31, 2020. The change was primarily due to lower borrowings partially offset by higher repurchases of Corteva common stock.

In January 2021, the Company's Board of Directors authorized a common stock dividend of $0.13 per share, payable on March 15, 2021, to the shareholders of record on March 1, 2021.

On June 26, 2019, the company's Board of Directors authorized a $1 billion share repurchase program to purchase Corteva, Inc.'s common stock, par value $0.01 per share, without an expiration date. The company repurchased $650 million under its share buyback plan since the Corteva Distribution and expects to repurchase the remaining $350 million in 2021. The timing, price and volume of purchases will be based on market conditions, relevant securities laws and other factors.

During the three months ended March 31, 2021, the company purchased and retired 7,646,000 shares in the open market for a total cost of $350 million. During the three months ended March 31, 2020, the company purchased and retired 1,865,000 shares for a total cost of $50 million. See Note 14 - Stockholders' Equity, to the interim Consolidated Financial Statements for additional information related to the share buyback plan.

EID Liquidity Discussion
As discussed in Note 1 - Basis of Presentation, to the EID Consolidated Financial Statements, EID is a subsidiary of Corteva, Inc. and continues to be a reporting company, subject to the requirements of the Exchange Act. The below relates to EID only and is presented to provide a Liquidity discussion for the differences between EID and Corteva, Inc.

Cash used for operating activities
EID’s cash used for operating activities was $1.9 billion for the three months ended March 31, 2021 and 2020, respectively. The change was primarily driven by the items above under the header, "Summary of Cash Flow".


51
Cash provided by financing activities
EID’s cash provided by financing activities was $0.8 billion for the three months ended March 31, 2021 compared to $2.3 billion for the three months ended March 31, 2020. The change was primarily driven by lower borrowings and higher payments on related party debt.

See Note 2 - Related Party Transactions, to the EID Consolidated Financial Statements for further information on the related party loan between EID and Corteva, Inc.

Guarantees and Off-Balance Sheet Arrangements
For detailed information related to Guarantees, Indemnifications, and Obligations for Equity Affiliates and Others, see the company’s 2020 Annual Report, Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations, Off-Balance Sheet Arrangements and Note 13 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements.


Contractual Obligations

Information related to the company's contractual obligations at December 31, 2020 can be found on page 73 of the company's 2020 Annual Report.  There have been no material changes to the company’s contractual obligations outside the ordinary course of business from those reported in the company’s 2020 Annual Report.


Item 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 

See Note 16 - Financial Instruments, to the interim Consolidated Financial Statements. See also Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk, of the company's 2020 Annual Report, for information on the company's utilization of financial instruments and an analysis of the sensitivity of these instruments.

52
Item 4.  CONTROLS AND PROCEDURES 

Corteva, Inc.

a)        Evaluation of Disclosure Controls and Procedures
 
The company maintains a system of disclosure controls and procedures to give reasonable assurance that information required to be disclosed in the company's reports filed or submitted under the Securities Exchange Act of 1934 ("Exchange Act") is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission. These controls and procedures also give reasonable assurance that information required to be disclosed in such reports is accumulated and communicated to management to allow timely decisions regarding required disclosures.

As of March 31, 2021, the company's Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO"), together with management, conducted an evaluation of the effectiveness of the company's disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, the CEO and CFO concluded that these disclosure controls and procedures are effective.
 
b)                         Changes in Internal Control over Financial Reporting
 
There have been no changes in the company's internal control over financial reporting that occurred during the quarter ended March 31, 2021 that have materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting.

E. I. du Pont de Nemours and Company

a)        Evaluation of Disclosure Controls and Procedures
 
EID maintains a system of disclosure controls and procedures to give reasonable assurance that information required to be disclosed in their reports filed or submitted under the Securities Exchange Act of 1934 ("Exchange Act") is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission. These controls and procedures also give reasonable assurance that information required to be disclosed in such reports is accumulated and communicated to management to allow timely decisions regarding required disclosures.

As of March 31, 2021, EID's CEO and CFO, together with management, conducted an evaluation of the effectiveness of EID's disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, the CEO and CFO concluded that these disclosure controls and procedures are effective.
 
b)                         Changes in Internal Control over Financial Reporting
 
There have been no changes in EID's internal control over financial reporting that occurred during the quarter ended March 31, 2021 that have materially affected, or are reasonably likely to materially affect, EID's internal control over financial reporting.
53
PART II.  OTHER INFORMATION


Item 1.LEGAL PROCEEDINGS
The company is subject to various legal proceedings, including, but not limited to, product liability, intellectual property, antitrust, commercial, property damage, personal injury, environmental and regulatory matters arising out of the normal course of its current businesses or legacy EID businesses unrelated to Corteva’s current businesses but allocated to Corteva as part of the Separation of Corteva from DuPont. Information regarding certain of these matters is set forth below and in Note 13 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements. Even when the Company believes liabilities are not expected to be material or the probability of loss or of an adverse unappealable final judgment is remote, the Company may consider settlement of these matters, and may enter into settlement agreements, if it believes settlement is in the best interest of the Company, including avoidance of future distraction and litigation defense cost, and its shareholders.

Litigation related to Corteva’s current businesses
Canadian Competition Bureau Formal Inquiry
On January 30, 2020, the Canadian Competition Bureau (the “Bureau”) filed a court order for the company to produce records and information as part of a formal inquiry under civil sections of Canada’s competition laws. The inquiry is in response to allegations by the Farmers Business Network ("FBN") that Corteva and other seeds and crop protection manufacturers and wholesalers unilaterally or in coordination refused, restricted and/or impaired supply of products to FBN in western Canada. This inquiry follows an informal request for information from the Bureau pursuant to which the company voluntarily provided documents and engaged in discussions with the Bureau outlining how its conduct was and continues to be compliant with Canadian competition laws. Corteva continues to cooperate with the Bureau’s inquiries, but believes the likelihood of material liability is remote.

Federal Trade Commission Investigation
On May 26, 2020, Corteva received a subpoena from the Federal Trade Commission (“FTC”) directing it to submit documents pertaining to its crop protection products generally, as well as business plans, rebate programs, offers, pricing and marketing materials specifically related to its acetochlor, oxamyl and rimsulfuron and other related products in order to determine whether Corteva engaged in unfair methods of competition through anticompetitive conduct. Corteva has cooperated with the FTC’s subpoena, and continues to believe the likelihood of material liability is remote.

Litigation related to legacy EID businesses unrelated to Corteva’s current businesses
As discussed below and in Note 13 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements, certain of the environmental proceedings and litigation allocated to Corteva as part of the Separation from DuPont relate to the legacy EID businesses, including their use of PFOA, which, for purposes of this report, means collectively perfluorooctanoic acid and its salts, including the ammonium salt and does not distinguish between the two forms, and PFAS, which means per- and polyfluoroalkyl substances, including PFOA, PFOS (perfluorooctanesulfonic acid), GenX and other perfluorinated chemicals and compounds ("PFCs"). Management believes that it is reasonably possible that EID could incur liabilities related to PFOA in excess of amounts accrued. However, any such losses are not estimable at this time due to various reasons, including, among others, that the underlying matters are in their early stages and have significant factual issues to be resolved.

On May 13, 2019, Chemours filed suit in the Delaware Court of Chancery against DuPont, EID, and Corteva, seeking, among other things, to limit its responsibility for the litigation and environmental liabilities allocated to and assumed by Chemours under the Chemours Separation Agreement (the “Delaware Litigation”). On March 30, 2020, the Court of Chancery granted a motion to dismiss. On December 15, 2020, the Delaware Supreme Court affirmed the judgment of the Court of Chancery. Meanwhile, a confidential arbitration process regarding the same and other claims has proceeded (the “Pending Arbitration”). On January 22, 2021, Chemours, DuPont, Corteva and EID entered into a binding memorandum of understanding containing a settlement to resolve legal disputes originating from the Delaware Litigation and Pending Arbitration, and to establish a cost sharing arrangement and escrow account to be used to support and manage potential future legacy per- and polyfluoroalkyl substances (“PFAS”) liabilities arising out of pre-July 1, 2015 conduct (the “MOU”). See Note 13 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements for further discussion.

Environmental Proceedings
The company believes it is remote that the following matters will have a material impact on its financial position, liquidity or results of operations. The matters below involve the potential for $1 million or more in monetary fines and are included per Item 103(3)(c)(iii) of Regulation S-K of the Securities Exchange Act of 1934, as amended.
54

Related to Corteva's current businesses

La Porte Plant, La Porte, Texas - Crop Protection - Release Incident Investigations
On November 15, 2014, there was a release of methyl mercaptan at EID's La Porte, Texas, facility. The release occurred at the site’s crop protection unit resulting in four employee fatalities inside the unit. The Chemical Safety Board (“CSB”) issued its final report on June 18, 2019, which included recommendations related to the emergency response program at La Porte. Corteva responded to the CSB on September 30, 2019 outlining the actions it has taken to date to address the recommendations for the site and providing its plan to address the CSB’s remaining recommendations. After the conclusion of the CSB investigation, criminal U.S. Environmental Protection Agency ("EPA") and the Department of Justice ("DOJ") investigations related to the incident continued. On January 8, 2021, EID and the facility's former unit operations leader were indicted by the DOJ on two felony and one misdemeanor charges of violations of the Clean Air Act related to the release. The maximum statutory penalties per charge are $500,000, or twice the gross gain or loss derived from the incident, as well as up to three years of probation and related ongoing reporting obligations. Corteva cooperated fully with the government’s investigation and will vigorously defend against these charges. The trial is currently scheduled for March 2022.

Related to legacy EID businesses unrelated to Corteva’s current businesses

Sabine Plant, Orange, Texas - EPA Multimedia Inspection
In June 2012, EID began discussions with the EPA and the DOJ related to a multimedia inspection that the EPA conducted at the Sabine facility in March 2009 and December 2015. The discussions involve the management of materials in the facility's wastewater treatment system, hazardous waste management, flare and air emissions, including leak detection and repair. These discussions continue. Under the Separation Agreement, Corteva and DuPont will share any future liabilities proportionally on the basis of 29% and 71%, respectively.

Divested Neoprene Facility, La Place, Louisiana - EPA Compliance Inspection
In 2016, the EPA conducted a focused compliance investigation at the Denka Performance Elastomer LLC (“Denka”) neoprene manufacturing facility in La Place, Louisiana. EID sold the neoprene business, including this manufacturing facility, to Denka in the fourth quarter of 2015. In the spring of 2017, the EPA, the DOJ, the Louisiana Department of Environmental Quality, EID and Denka began discussions relating to the inspection conclusions and allegations of noncompliance arising under the Clean Air Act, including leak detection and repair. These discussions, which include potential settlement options, continue. Under the Separation Agreement, DuPont is defending and indemnifying the company in this matter.

New Jersey Directive PFAS
On March 25, 2019, the New Jersey Department of Environmental Protection (“NJDEP”) issued a Statewide PFAS Directive to several companies, including Chemours, DuPont, and EID. The Directive seeks information relating to the use and environmental release of PFAS and PFAS-replacement chemicals at and from two former EID sites in New Jersey, Chambers Works and Parlin, and a funding source for costs related to the NJDEP’s investigation of PFAS issues and PFAS testing and remediation.

New Jersey Directive Pompton Lakes
On March 27, 2019, the NJDEP issued to Chemours and EID a Natural Resource Damages Directive relating to chemical contamination (non-PFAS) at and around EID’s former Pompton Lakes facility in New Jersey. The Directive alleges that this contamination has harmed the natural resources of New Jersey. It seeks $125,000 as reimbursement for the cost of preparing a natural resource damages assessment, which the State will use to determine the extent of such damage and the amount it expects to seek to restore the affected natural resources to their pre-damage state.

Natural Resource Damage Cases
Since May 2017, several municipal water districts and state attorneys general have filed lawsuits against EID, Corteva, Chemours, 3M, and others, claiming contamination of public water systems by PFCs, including but not limited to PFOA. These actions with the municipalities and states seeking economic impact damages for alleged harm to natural resources, punitive damages, present and future costs to cleanup PFOA contamination and the abatement of alleged nuisance with filtration systems. Further information with respect to these proceedings is set forth under "Other PFOA Matters" in Note 13 - Commitments and Contingent Liabilities, to the interim Consolidated Financial Statements.

55
Item 1A. RISK FACTORS

There have been no material changes in the company's risk factors discussed in Part I, Item 1A, Risk Factors, in the company's most recently filed annual report on Form 10-K.

56
Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Issuer Purchases of Equity Securities
The following table summarizes information with respect to the company's purchase of its common stock during the three months ended March 31, 2021:
Month Total Number of Shares Purchased Average Price
Paid per Share
Total Number of
Shares Purchased as Part of the Company's Publicly Announced Share Buyback Program1
Approximate Value
of Shares that May
Yet Be Purchased
Under the Programs(1) (Dollars in millions)
February 2021 2,530,263  $ 44.78  2,530,263  $ 587 
March 2021 5,116,171  46.27  5,116,171  350
Total 7,646,434  $ 45.77  7,646,434  $ 350 
1.    On June 26, 2019, Corteva, Inc. announced that its Board of Directors authorized a $1 billion share repurchase program to purchase Corteva, Inc.'s common stock, par value $0.01 per share, without an expiration date. The timing, price and volume of purchases will be based on market conditions, relevant securities laws and other factors.

57

Item 5. OTHER INFORMATION

None.
58
Item 6.EXHIBITS

Exhibit
Number 		  Description
     
2.1
Separation and Distribution Agreement by and among DuPont Inc., Dow Inc. and Corteva, Inc. (incorporated by reference to Exhibit No. 2.1 to Amendment 3 to Corteva’s Registration Statement on Form 10 (Commission file number 001-38710), filed on April 16, 2019).
     
3.1
  Amended and Restated Certificate of Incorporation of Corteva, Inc. (incorporated by reference to Exhibit No. 3.1 to Corteva’s Current Report on Form 8-K (Commission file number 001-38710), filed on June 3, 2019.
     
3.2
  Amended and Restated Bylaws of Corteva, Inc. (incorporated by reference to Exhibit No. 3.1 to Corteva’s Current Report on Form 8-K (Commission file number 001-38710), filed on October 10, 2019.
     
3.3
Amended and Restated Certificate of Incorporation of E.I. du Pont de Nemours and Company (incorporated by reference to Exhibit 3.1 to E.I. du Pont de Nemours and Company’s Current Report on Form 8-K (Commission file number 1-815) dated September 1, 2017).
3.4
Amended and Restated Bylaws of E.I. du Pont de Nemours and Company (incorporated by reference to Exhibit 3.2 to E.I. du Pont de Nemours and Company's Current Report on Form 8-K (Commission file number 1-815) dated September 1, 2017).
4   Corteva agrees to provide the Commission, on request, copies of instruments defining the rights of holders of long-term debt of Corteva and its subsidiaries.
Master Repurchase Agreement by and among Coöperatieve Rabobank, U.A. (New York Branch), MUFG Bank, Ltd. (New York Branch), Standard Chartered Bank (New York Branch), HSBC Bank USA, N.A., and PHI Financial Services, Inc. dated as of February 9, 2021.
Master Framework Agreement by and among Coöperatieve Rabobank, U.A. (New York Branch), MUFG Bank, Ltd. (New York Branch), Standard Chartered Bank (New York Branch), HSBC Bank USA, N.A., and PHI Financial Services, Inc. dated as of February 9, 2021.
Memorandum of Understanding, dated January 22, 2021, by and among The Chemours Company, Corteva, Inc., E. I. du Pont de Nemours and Company and DuPont de Nemours, Inc. (incorporated by reference from the Form 8-K (Commission file number 001-38710) filed January 22, 2021)
Agreement dated March 18, 2021, among Corteva, Inc., Starboard Value LP and certain of its affiliates (incorporated by reference from the Form 8-K (Commission file number 001-38710) filed March 19, 2021).
     
  Rule 13a-14(a)/15d-14(a) Certification of the company’s and EID’s Principal Executive Officer.
     
  Rule 13a-14(a)/15d-14(a) Certification of the company’s and EID’s Principal Financial Officer.
   
  Section 1350 Certification of the company’s and EID’s Principal Executive Officer. The information contained in this Exhibit shall not be deemed filed with the Securities and Exchange Commission nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended.
     
  Section 1350 Certification of the company’s and EID’s Principal Financial Officer. The information contained in this Exhibit shall not be deemed filed with the Securities and Exchange Commission nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended.
101.INS   XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
     
101.SCH   Inline XBRL Taxonomy Extension Schema Document
     
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 Cover Page Interactive Data File – The Cover Page XBRL tags are embedded within the Inline XBRL document (included in Exhibit 101.INS)
59
SIGNATURE

Corteva, Inc. 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
CORTEVA, INC.
(Registrant)
   
Date: May 5, 2021
   
   
By: /s/ Brian Titus
 
  Brian Titus
  Vice President, Controller
  (Principal Accounting Officer)

E. I. du Pont de Nemours and Company

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
E. I. du Pont de Nemours and Company
(Registrant)
   
Date: May 5, 2021
   
   
By: /s/ Brian Titus
 
  Brian Titus
  Vice President, Controller
  (Principal Accounting Officer)


60
CONSOLIDATED FINANCIAL STATEMENTS OF E. I. DU PONT DE NEMOURS AND COMPANY

E. I. du Pont de Nemours and Company
Consolidated Statements of Operations (Unaudited) 
Three Months Ended
March 31,
(In millions, except per share amounts) 2021 2020
Net sales $ 4,178  $ 3,956 
Cost of goods sold
2,420  2,269 
Research and development expense
281  280 
Selling, general and administrative expenses
733  757 
Amortization of intangibles
183  163 
Restructuring and asset related charges - net
100  70 
Other income - net
337  1 
Interest expense
22  42 
Income from continuing operations before income taxes 776  376 
Provision for income taxes on continuing operations 174  119 
Income from continuing operations after income taxes 602  257 
(Loss) income from discontinued operations after income taxes (10) 1 
Net income 592  258 
Net income attributable to noncontrolling interests 1  8 
Net income attributable to E. I. du Pont de Nemours and Company $ 591  $ 250 

See Notes to the Consolidated Financial Statements beginning on page 66.


61
E. I. du Pont de Nemours and Company
Consolidated Statements of Comprehensive Income (Loss) (Unaudited)
Three Months Ended
March 31,
(In millions) 2021 2020
Net income $ 592  $ 258 
Other comprehensive loss - net of tax:
Cumulative translation adjustments
(403) (672)
Adjustments to pension benefit plans
8  — 
Adjustments to other benefit plans
(157) 3 
Unrealized gain on investments 10  — 
Derivative instruments
65  6 
Total other comprehensive loss (477) (663)
Comprehensive income (loss) 115  (405)
Comprehensive income attributable to noncontrolling interests - net of tax 1  8 
Comprehensive income (loss) attributable to E. I. du Pont de Nemours and Company $ 114  $ (413)

See Notes to the Consolidated Financial Statements beginning on page 66.

62
E. I. du Pont de Nemours and Company
Condensed Consolidated Balance Sheets (Unaudited)
(In millions, except share amounts) March 31, 2021 December 31, 2020 March 31, 2020
Assets    
Current assets    
Cash and cash equivalents $ 2,404  $ 3,526  $ 1,963 
Marketable securities 114  269  10 
Accounts and notes receivable - net 6,792  4,926  6,775 
Inventories 4,321  4,882  4,401 
Other current assets 1,405  1,165  1,530 
Total current assets 15,036  14,768  14,679 
Investment in nonconsolidated affiliates 64  66  64 
Property, plant and equipment - net of accumulated depreciation (March 31, 2021 - $3,874; December 31, 2020 - $3,857; March 31, 2020 - $3,406) 4,299  4,396  4,358 
Goodwill 10,146  10,269  10,027 
Other intangible assets 10,584  10,747  11,241 
Deferred income taxes 433  464  273 
Other assets 1,987  1,939  2,336 
Total Assets
$ 42,549  $ 42,649  $ 42,978 
Liabilities and Equity    
Current liabilities    
Short-term borrowings and finance lease obligations $ 1,250  $ 3  $ 1,996 
Accounts payable 3,098  3,615  3,021 
Income taxes payable 165  123  143 
Deferred revenue 2,247  2,662  1,996 
Accrued and other current liabilities 2,257  2,148  2,083 
Total current liabilities
9,017  8,551  9,239 
Long-Term Debt 1,102  1,102  614 
Long-Term Debt - Related Party 3,012  3,459  3,872 
Other Noncurrent Liabilities
Deferred income tax liabilities
902  893  911 
Pension and other post employment benefits - noncurrent
4,954  5,176  6,186 
Other noncurrent obligations
1,814  1,867  1,989 
Total noncurrent liabilities
11,784  12,497  13,572 
Commitments and contingent liabilities
Stockholders’ equity    
Preferred stock, without par value – cumulative; 23,000,000 shares authorized;
     issued at March 31, 2021, December 31, 2020, and March 31, 2020:
$4.50 Series – 1,673,000 shares (callable at $120)
169  169  169 
$3.50 Series – 700,000 shares (callable at $102)
70  70  70 
Common stock, $0.30 par value; 1,800,000,000 shares authorized; 200 issued at March 31, 2021, December 31, 2020, and March 31, 2020 —  —  — 
Additional paid-in capital 24,083  24,049  24,004 
Retained earnings / (accumulated deficit) 792  203  (158)
Accumulated other comprehensive loss (3,367) (2,890) (3,933)
Total E. I. du Pont de Nemours and Company stockholders’ equity
21,747  21,601  20,152 
Noncontrolling interests
1  —  15 
Total equity
21,748  21,601  20,167 
Total Liabilities and Equity
$ 42,549  $ 42,649  $ 42,978 

See Notes to the Consolidated Financial Statements beginning on page 66.

63
E. I. du Pont de Nemours and Company
Consolidated Statements of Cash Flows (Unaudited)
Three Months Ended
March 31,
(In millions) 2021 2020
Operating activities
Net income $ 592  $ 258 
Adjustments to reconcile net income to cash used for operating activities:
Depreciation and amortization 304  283 
Provision for deferred income tax 47  26 
Net periodic pension and OPEB benefit, net (318) (85)
Pension and OPEB contributions (84) (95)
Net loss on sales of property, businesses, consolidated companies, and investments —  46 
Restructuring and asset related charges - net 100  70 
Other net loss 54  138 
Changes in assets and liabilities, net
Accounts and notes receivable (2,012) (1,685)
Inventories 467  398 
Accounts payable (448) (557)
Deferred revenue (401) (575)
Other assets and liabilities (247) (144)
Cash used for operating activities (1,946) (1,922)
Investing activities  
Capital expenditures (137) (128)
Proceeds from sales of property, businesses, and consolidated companies - net of cash divested 20  11 
Purchases of investments (40) (67)
Proceeds from sales and maturities of investments 194  58 
Other investing activities - net (1) (4)
Cash provided by (used for) investing activities 36  (130)
Financing activities  
Net change in borrowings (less than 90 days) 828  1,619 
Payments on related party debt (447) (148)
Proceeds from debt 419  875 
Payments on debt —  (1)
Proceeds from exercise of stock options 38  14 
Other financing activities (21) (23)
Cash provided by financing activities 817  2,336 
Effect of exchange rate changes on cash, cash equivalents and restricted cash (50) (117)
(Decrease) / increase in cash, cash equivalents and restricted cash (1,143) 167 
Cash, cash equivalents and restricted cash at beginning of period 3,873  2,173 
Cash, cash equivalents and restricted cash at end of period $ 2,730  $ 2,340 
See Notes to the Consolidated Financial Statements beginning on page 66.
64
E. I. du Pont de Nemours and Company
Consolidated Statements of Equity (Unaudited)
(In millions) Preferred Stock Common Stock Add. Paid-in Capital "APIC" Retained Earnings (Accumulated deficit) Accum. Other Comp Loss Treasury Stock Non-controlling Interests Total Equity
2020
Balance at January 1, 2020 $ 239  $ —  $ 23,958  $ (406) $ (3,270) $ —  $ 7  $ 20,528 
Net income
250  8  258 
Other comprehensive loss
(663) (663)
Preferred dividends ($4.50 Series - $1.125 per share, $3.50 Series - $0.875 per share) (2) (2)
Issuance of Corteva stock 14  14 
Share-based compensation
2  2 
Other - net
32  (2) 30 
Balance at March 31, 2020 $ 239  $ —  $ 24,004  $ (158) $ (3,933) $ —  $ 15  $ 20,167 
(In millions) Preferred Stock Common Stock Add. Paid-in Capital "APIC" Retained Earnings (Accumulated deficit) Accum. Other Comp Loss Treasury Stock Non-controlling Interests Total Equity
2021
Balance at January 1, 2021 $ 239  $ —  $ 24,049  $ 203  $ (2,890) $ —  $ —  $ 21,601 
Net income 591  1  592 
Other comprehensive loss (477) (477)
Preferred dividends ($4.50 Series - $1.125 per share, $3.50 Series - $0.875 per share) (2) (2)
Issuance of Corteva stock 38  38 
Other - net (4) (4)
Balance at March 31, 2021 $ 239  $ —  $ 24,083  $ 792  $ (3,367) $ —  $ 1  $ 21,748 

See Notes to the Consolidated Financial Statements beginning on page 66.
65
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

E. I. du Pont de Nemours and Company
Notes to the Consolidated Financial Statements (Unaudited)


Table of Contents

66
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 1 - BASIS OF PRESENTATION

As a result of the Business Realignment and the Internal Reorganization, Corteva, Inc. owns 100% of the outstanding common stock of EID. EID is a subsidiary of Corteva, Inc. and continues to be a reporting company, subject to the requirements of the Exchange Act. The primary differences between Corteva, Inc. and EID are outlined below:

•Preferred Stock - EID has preferred stock outstanding to third parties which is accounted for as a non-controlling interest at the Corteva, Inc. level. Each share of EID Preferred Stock - $4.50 Series and EID Preferred Stock - $3.50 Series issued and outstanding at the effective date of the Corteva Distribution remains issued and outstanding as to EID and was unaffected by the Corteva Distribution.
•Related Party Loan - EID engaged in a series of debt redemptions during the second quarter of 2019 that were partially funded through an intercompany loan from Corteva, Inc. This was eliminated in consolidation at the Corteva, Inc. level but remains on EID's financial statements at the standalone level (including the associated interest).
•Capital Structure - At March 31, 2021, Corteva, Inc.'s capital structure consists of 738,321,000 issued shares of common stock, par value $0.01 per share.

The accompanying footnotes relate to EID only, and not to Corteva, Inc., and are presented to show differences between EID and Corteva, Inc.

For the footnotes listed below, refer to the following Corteva, Inc. footnotes:
•Note 1 - Summary of Significant Accounting Policies - refer to page 9 of the Corteva, Inc. interim Consolidated Financial Statements
•Note 2 - Recent Accounting Guidance - refer to page 9 of the Corteva, Inc. interim Consolidated Financial Statements
•Note 3 - Divestitures and Other Transactions - refer to page 9 of the Corteva, Inc. interim Consolidated Financial Statements
•Note 4 - Revenue - refer to page 10 of the Corteva, Inc. interim Consolidated Financial Statements
•Note 5 - Restructuring and Asset Related Charges - Net - refer to page 13 of the Corteva, Inc. interim Consolidated Financial Statements
•Note 6 - Supplementary Information - refer to page 14 of the Corteva, Inc. interim Consolidated Financial Statements
•Note 7 - Income Taxes - refer to page 16 of the Corteva, Inc. interim Consolidated Financial Statements
•Note 8 - Earnings Per Share of Common Stock - Not applicable for EID
•Note 9 - Accounts and Notes Receivable - Net - refer to page 18 of the Corteva, Inc. interim Consolidated Financial Statements
•Note 10 - Inventories - refer to page 19 of the Corteva, Inc. interim Consolidated Financial Statements
•Note 11 - Other Intangible Assets - refer to page 19 of the Corteva, Inc. interim Consolidated Financial Statements
•Note 12 - Short-Term Borrowings, Long-Term Debt and Available Credit Facilities - refer to page 20 of the Corteva, Inc. interim Consolidated Financial Statements. In addition, EID has a related party loan payable to Corteva, Inc.; refer to EID Note 2 - Related Party Transactions, below
•Note 13 - Commitments and Contingent Liabilities - refer to page 21 of the Corteva, Inc. interim Consolidated Financial Statements
•Note 14 - Stockholders' Equity - refer to page 26 of the Corteva, Inc. interim Consolidated Financial Statements
•Note 15 - Pension Plans and Other Post Employment Benefits - refer to page 29 of the Corteva, Inc. interim Consolidated Financial Statements
•Note 16 - Financial Instruments - refer to page 29 of the Corteva, Inc. interim Consolidated Financial Statements
•Note 17 - Fair Value Measurements - refer to page 35 of the Corteva, Inc. interim Consolidated Financial Statements
•Note 18 - Segment Information - Differences exist between Corteva, Inc. and EID; refer to EID Note 3 - Segment Information, below


67
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 2 - RELATED PARTY TRANSACTIONS

Transactions with Corteva
In the second quarter of 2019, EID entered into a related party revolving loan from Corteva, Inc., with a maturity date in 2024. As of March 31, 2021, December 31, 2020, and March 31, 2020, the outstanding related party loan balance was $3,012 million, $3,459 million, and $3,872 million respectively (which approximates fair value), with interest rates of 1.62% at March 31, 2021 and December 31, 2020, respectively, and 3.27% at March 31, 2020, and is reflected as long-term debt - related party in EID's interim Condensed Consolidated Balance Sheets. Additionally, EID has incurred tax deductible interest expense of $15 million and $32 million for the three months ended March 31, 2021 and 2020, respectively, associated with the related party loan from Corteva, Inc.

As of March 31, 2021, EID had payables to Corteva, Inc., of $55 million and $91 million included in accrued and other current liabilities and other noncurrent obligations, respectively, $92 million at December 31, 2020 included in both accrued and other current liabilities and other noncurrent obligations, respectively, and $166 million and $82 million at March 31, 2020, included in accrued and other current liabilities and other noncurrent obligations, respectively, in the interim Condensed Consolidated Balance Sheets related to Corteva's indemnification liabilities to Dow and DuPont per the Separation Agreements (refer to page 9 of the Corteva, Inc. interim Consolidated Financial Statements for further details of the Separation Agreements).

NOTE 3 - SEGMENT INFORMATION

There are no differences in reporting structure or segments between Corteva, Inc. and EID. In addition, there are no differences between Corteva, Inc. and EID segment net sales, segment operating EBITDA, segment assets, or significant items by segment; refer to page 36 of the Corteva, Inc. interim Consolidated Financial Statements for background information on the segments as well as further details regarding segment metrics. The tables below reconcile income from continuing operations after income taxes to segment operating EBITDA, as differences exist between Corteva, Inc. and EID.

Reconciliation to interim Consolidated Financial Statements
Income from continuing operations after income taxes to segment operating EBITDA


(In millions)
Three Months Ended
March 31,
2021 2020
Income from continuing operations after income taxes $ 602  $ 257 
Provision for income taxes on continuing operations 174  119 
Income from continuing operations before income taxes 776  376 
Depreciation and amortization 304  283 
Interest income (21) (18)
Interest expense 22  42 
Exchange losses - net 35  61 
Non-operating benefits - net (311) (73)
Mark-to-market gains on certain foreign currency contracts not designated as hedges1
(1)
Significant items 100  123 
Corporate expenses 34  25 
Segment operating EBITDA $ 938  $ 819 
1.Effective January 1, 2021, on a prospective basis, the company excludes net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting. There was no activity in the three months ended March 31, 2020.

68
EIDP (NYSE:CTA-B)
過去 株価チャート
から 11 2024 まで 12 2024 EIDPのチャートをもっと見るにはこちらをクリック
EIDP (NYSE:CTA-B)
過去 株価チャート
から 12 2023 まで 12 2024 EIDPのチャートをもっと見るにはこちらをクリック